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TSLP-induced Mechanisms and Potential Therapies for 
CRLF2 B-cell Acute Lymphoblastic Leukemia 
 
by 
Olivia L Francis  
Doctor of Philosophy, Graduate Program in Anatomy  
Loma Linda University, June 2015 
Dr. Kimberly J Payne, Chairperson 
 
Childhood CRLF2 B-cell Acute Lymphoblastic Leukemia (CRLF2 B-ALL) is a 
high-risk form of leukemia that is associated with poor patient survival outcomes. CRLF2 
B-ALL is five times more prevalent in Hispanic children than others and is associated 
with a higher rate of relapse, thus contributing significantly to childhood cancer health 
disparities. This disease occurs due to alterations of the CRLF2 gene, leading to over-
expression of the CRLF2 protein- a component of the receptor signaling complex for the 
cytokine Thymic Stromal LymphoPoietin (TSLP) on the surface of B-ALL cells. TSLP 
has been shown to induce proliferation of human and mouse B-cell precursors via 
activation of the JAK-STAT5 and more recently the PI3K/AKT/mTOR pathways.  
However, the mechanisms by which TSLP-CRLF2 interactions contribute to high-risk 
leukemia have not been elucidated. Therefore the objective of our studies was to 
elucidate the TSLP-induced mechanisms that contribute to high-risk CRLF2 B-ALL and 
to evaluate promising drug candidates to target high-risk B-ALL. Based on literature 
findings and preliminary data, we hypothesized that TSLP contributes to CRLF2 B-ALL 
by increasing proliferation and/or survival of leukemia cells via regulation of genes 
downstream of CRLF2 pathway activation. This hypothesis was tested using experiments 
xvii 
developed under the following specific aims:- Aim 1: Optimize the novel hTSLP+/- 
xenograft model for use in defining the role of TSLP in CRLF2 B-ALL; Aim 2:  Identify 
TSLP-induced cellular and molecular mechanisms that contribute to CRLF2 B-ALL; 
Aim 3: Assess  candidate  drugs’  efficacy  against high-risk B-ALL. Results from the 
studies conducted to address the specific aims show that 1) the hTSLP+/hTSLP- mouse 
model produces detectable levels of hTSLP, which activates CRLF2 and expands normal 
B-cells and activates the mTOR cell survival pathway in CRLF2 B-ALL cells in vivo; 2) 
cellular assays of apoptosis along with gene expression data demonstrate that TSLP 
regulates the expression of genes that promote cell death and survival of CRLF2 B-ALL 
cells in vivo and in vitro; 3) drug efficacy studies performed on high-risk leukemia cells 
using several drug candidates demonstrate that the Mcl-1 inhibitor MIM1 and the 
Novomedix drug series induced cell death in CRLF2 B-ALL and Nalm6 cells 
respectively. Taken together, the data provide evidence that TSLP regulates cell survival 
mechanisms in CRLF2 B-ALL cells and provides a rationale for the use of combination 
therapies that include drugs which target cell survival molecules and/or cellular functions 
regulated by TSLP.  
 
1 
CHAPTER ONE 
INTRODUCTION 
 
Normal B-cell Development 
Stages of Early B-cell Differentiation 
Human B-cells are derived from hematopoietic stem cells (HSCs) in the bone 
marrow (BM), where they undergo lineage specific changes to develop into mature B-
cells [1]. HSCs produce multi-potent progenitors (MPPs) which give rise to lymphoid-
primed MPPs (LMPPs) followed by common lymphoid progenitors (CLPs). CLPs then 
differentiate through the following consecutive B-cell stages to produce functional B-
cells: Pro-B, Pre-B, Immature-B and Mature B (Figure 1.1)[2]. The pro-B to pre-B 
transition requires successful rearrangement and expression of genes that encode the 
immunoglobulin heavy chain (IGHµ), specifically the gene segments from the germ line- 
variable, diversity and joining regions during VDJ recombination [3-4]. This process is 
facilitated by recombination activating genes 1 and 2 (RAG1 and RAG2) [3]. 
Approximately 1/3 of the pro-B cells successfully express the IgHµ chain and a surrogate 
light chain (SLC) in their cytoplasm along with a pre-BCR on their surface, becoming 
pre-B cells. This transition is often referred to as the first checkpoint [1, 5]. These pre-B 
cells then undergo polyclonal expansion (proliferation of cells that have successfully 
rearranged IGH) and prepare to rearrange their light chain.  
The pre-B to immature-B transition is characterized by rearrangement of genes 
that encode the immunoglobulin  light  chain  (Igκ  then  Igλ), and the suppression of SLC as 
well as pre-BCR [1, 4]. This transition is the second checkpoint. Successful 
rearrangements of both heavy and light chains contribute to the generation of a diverse 
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antibody repertoire [3]. B-cells that fail to successfully rearrange and express functional 
IgH and IgL chains are removed by programmed cell death also known as apoptosis[6]. 
The mature B-cells produced by this process express surface immunoglobulin M (IgM) 
and subsequently undergo class switch recombination to produce a variety of antibody 
isotypes (IgA, IgD, IgE, IgG) with high antigen specificity and affinity. The B-cells then 
migrate to secondary lymphoid organs where they are able to mount a robust humoral 
response against pathogens as part of the adaptive immune system machinery [7]. 
 
 
Fig.1.1 Stages of Early B-cell Differentiation 
 
Cytokine Function in Normal B-cells 
In order for the complex process of B-cell differentiation to occur, developing B-
cells depend on extrinsic factors that are present in the BM microenvironment including 
non-hematopoietic cells such as stromal cells and the factors that they secrete [8]. In the 
bone marrow, B-cells associate with bone marrow stromal cells (BMSCs) which have 
been described as progenitors of skeletal, muscle and neural tissues [9]. In addition to 
their functions listed above, these BMSCs support the development of hematopoietic 
(blood) cells including B-cells by secreting cytokines (growth factors) that are required 
3 
for the B-cells to develop [1, 10]. Cytokines are peptides or glycoproteins that promote 
cell growth, differentiation and/or survival [1].  
CXCL12, Flt3, and interleukin 7 (IL-7) are among cytokines that are produced by 
BMSCs and are required for the development of B-cells [1]. Specifically, IL-7 is required 
for the survival, expansion and differentiation of mouse B-cell precursors [11-13]. Our 
lab has demonstrated that IL-7 induces the expansion of human Pro-B cells, which is 
crucial for providing large cell numbers to progress through the stages of B-cell 
differentiation [14]. The cytokine Thymic Stromal Lymphopoietin (TSLP), which is 
produced by epithelial cells of the lung and skin as well as BMSCs has also been shown 
to contribute to B-development [15-16]. In addition to activating dendritic cells, 
regulating inflammation and contributing to asthma and allergic responses; TSLP also 
induces proliferation in human pro-B cells and promotes B-cell survival by protecting 
cells from apoptosis, [17-20][Milford unpub. data].  
 
TSLP and IL-7 Signaling in Normal B-cells 
 Cytokines interact with their receptors, which are often found on the 
surface or within a cell, to activate signal transduction pathways and in turn promote cell 
survival, proliferation and differentiation [10]. TSLP performs its function in B-cells by 
binding to its receptor, which comprises of two subunits: IL-7Rα  and  TSLPR  (also  
known as CRLF2). Upon binding to its receptor, TSLP traditionally activates the JAK-
STAT pathway [10, 21]. TSLP binds its receptor subunits, which dimerize leading to the 
recruitment and activation of Janus kinases (JAK1 and JAK2) via cross-phosphorylation 
followed by phosphorylation of tyrosine residues found in the cytoplasmic domain of the 
4 
receptors [22]. Signal transducers and activators of transcription-STAT (primarily 
STAT5) proteins- bind to the tyrosine-phosphorylated receptors via their SH2 domains 
and become phosphorylated by the JAKs [22]. STATs then dissociate from the receptors, 
form dimers, translocate to the nucleus and bind to the promoter of target genes in order 
to regulate gene transcription. Studies have shown that STAT5 regulates B-cell survival 
and differentiation; a process that is mediated by the Bcl2 family members [23]. More 
recently, it has been shown that in addition to the JAK-STAT pathway, TSLP also binds 
its receptor and signals through other downstream pathways such as the PI3K/AKT and 
mTOR pathways [24-25][appdx]. It is important to note that IL-7 shares the IL-7Rα,  
which has implications for studies discussed later in this dissertation (Figure.1.2). To 
perform its functions, IL-7 binds to its receptor which comprises of two subunits: IL-7Rα  
and IL-2Rγ  and  also  activates  the  JAK-STAT pathway [21]. IL-7 binds its receptor and 
follows the signal transduction cascade described above for TSLP, with the exception 
that IL-7 signals through JAK1 and JAK3 [22].  
 
 
Fig.1.2 TSLP and IL-7 Receptors 
 
The Role of Transcription Factors in Normal B-cells 
Several transcription factors primarily Ikaros, PU.1, EBF, E2A and Pax5 all work 
in concert to regulate the early stages of B-cell development (Figure 1.1)[26]. These 
5 
transcription factors function to activate or repress genes that are responsible for ensuring 
B-cell lineage commitment during each stage of differentiation [26]. PU.1 regulates 
lymphoid versus myeloid differentiation [2]. E2A maintains the stem cell pool, is 
required to promote the lymphoid lineage at the LMPP and CLP stages and it turns on 
and maintains the expression of EBF and Pax5 [27]. EBF regulates the genes that are 
required for producing B-cells such as Pax5.  Pax5 is absolutely required for maintaining 
B-cell identity; in the absence of Pax5, cells de-differentiate to a progenitor stage where 
they can commit to other lineages such as the T-lineage [28-29]. Ikaros promotes B-cell 
development by regulating chromatin availability required for VDJ recombination, 
regulating B-cell related genes and contributing to commitment to the B-lineage [2]. As a 
result, B-cell differentiation is a tightly regulated process that is controlled by interactions 
between transcription factors, the cytokines they regulate and the cellular processes that 
occur during differentiation. 
 
High-risk B-cell Acute Lymphoblastic Leukemia 
Despite this tightly regulated process, aberrations can occur at various 
developmental stages leading to B-cell related diseases such as lymphoma, autoimmune 
diseases and leukemia [30-31]. Recent studies show that the dysregulation of genes 
involved in B-cell differentiation, survival, proliferation and cell cycle contribute to 
human leukemogenesis [32-35]. B-cell differentiation is blocked at the B-cell precursor 
(BCP) stage where cells are rapidly proliferating due to genetic alterations in 
transcription factors e.g. IKaros and Pax5, leading to the development of B-cell Acute 
Lymphoblastic Leukemia (B-ALL) [36]. The loss of mechanisms that would normally 
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induce apoptosis in B-cells that fail to differentiate, causes these aberrantly proliferating 
cells to survive [37]. B-ALL is characterized by rapid accumulation of malignant B-cells 
in the BM compared to other cell types.  
Studies have identified several subtypes of B-ALL in which patients are resistant 
to chemotherapy and suffer high rates of relapse, often resulting in death. These patients 
are  referred  to  as  “high-risk” patients. High-risk patients are identified based on several 
clinical features at diagnosis such as white blood cell count, age, ethnicity, cytogenic 
abnormalities, response to treatment and minimal residual disease. After assessment, risk 
classification schemes are used to place patients into low-risk, medium-risk or high-risk 
categories [38]. Cytogenic abnormalities such as genetic mutations, genetic deletions and 
chromosomal translocations are identified using genome wide association studies that 
screen high-risk B-ALL patient samples [33, 39].  
These studies proved useful in that they reported high-risk B-ALL patients as 
having translocations such as BCR-ABL (also known as Philadelphia chromosome-
positive (Ph+)) or mutations and/or deletions in the IKZF1 and CRLF2 genes [40-41] . 
More recently, a high-risk subset of B-ALL was identified. This subset is referred to as 
BCR-ABL-like or Ph-like ALL. Patients in this subset have a similar genetic profile to 
Ph+ B-ALL, but lack the BCR-ABL fusion protein [41]. This subset is characterized by 
an increased occurrence of IKZF1 gene defects and 50% of these patients have CRLF2 
gene alterations [41]. The CRLF2 gene alterations include a translocation between the 
IGH promoter and the CRLF2 gene producing a fusion transcript or an intra-
chromosomal deletion that forms a P2RY8-CRLF2 fusion transcript [41-42]. The CRLF2 
genetic defects lead to the over-expression of the CRLF2 protein (the receptor component 
7 
for TSLP) on the surface of B-ALL cells and this subset of B-ALL is referred to as 
CRLF2 B-ALL.  
 
Significance of Study 
Identifying Molecular Targets in CRLF2 Signaling Pathway 
ALL is the most common childhood malignancy and B-ALL accounts for 80% of 
these cases [37]. With current therapies, ~25% of pediatric B-ALL patients still relapse 
and ~15% of these children are most likely to fail therapy and die [38]. The high-risk Ph-
like B-ALL accounts for 10-15% of childhood B-ALL. Though Ph-like B-ALL has a 
heterogeneous genetic profile (unlike Ph+ B-ALL), ~50% of this subset of B-ALL have 
genetic defects in the CRFL2 gene [41]. The translocation leading to the BCR-ABL+ B-
ALL subtype was the first of the genetic alterations to be identified and tyrosine kinase 
inhibitors (TKIs) that specifically target the aberrant kinase activity produced by the 
BCR-ABL translocation have been developed into drugs and are currently used to treat 
patients [43-44]. This provides a paradigm for targeting pathways that are activated as a 
result of genetic defects that are associated with high-risk leukemia. Despite the progress 
made in relation to the survival outcomes of patients with the BCR-ABL translocation, 
the survival outcomes of patients with CRLF2 gene defects continue to experience poor 
survival outcomes. Further, the mechanism of disease and downstream molecular 
mediators that contribute to CRLF2 B-ALL remains to be elucidated. The studies 
described in the subsequent chapters of this dissertation are significant because they 
identified molecular targets in the CRLF2 signaling pathway that regulate CRLF2 B-ALL 
cell survival and can serve as druggable targets. 
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Reducing Childhood Cancer Health Disparities 
For ten years we have known that Hispanic children are more likely to develop 
ALL (1.2 times more likely) and when they do, they are more likely to die (39% higher 
death rate) when compared to other children [45]. Genome-wide association studies of 
samples from high-risk B-ALL patients revealed that CRLF2 B-ALL is five times more 
prevalent in Hispanic children and they experience a higher rate of relapse and an overall 
poorer prognosis [46]. This is further accentuated in geographical locations where there is 
a dense population of Hispanics such as California. Thus, over-expression of CRLF2 is 
one of most significant biological components of childhood cancer health disparities 
identified to date and is likely a major contributor to the increased incidence and higher 
mortality rate for ALL in Hispanic children. Most of the health disparity studies 
conducted so far focus on 1) examining the relationship between ethnicity and mortality; 
2) the relationship between ethnicity and treatment outcomes and 3) the prevalence of 
genetic defects and ancestry-related genetic alterations such as single nucleotide 
polymorphisms [46-48]. The studies described in this dissertation are significant because 
we identified TSLP-induced biological pathways and molecules that regulate the survival 
of CRLF2 B-ALL, which is most prevalent among Hispanics. Additionally, the animal 
model we developed provides a tool that can be used to study the mechanisms of CRLF2 
B-ALL in Hispanic patient samples. The results from these studies offer the potential to 
identify biological factors that contribute to the health disparity observed in Hispanic 
children and can be targeted with appropriate therapies to improve survival outcomes, 
thereby alleviating the disparity. 
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Identifying Therapies to Target CRLF2 Signaling Pathway 
Improved remission rates in recent years are primarily due to the administration of 
higher doses of standard chemotherapy [49]. Despite the success of current therapeutic 
strategies with some high-risk B-ALL such as Ph+ B-ALL, CRLF2 B-ALL patients still 
experience a 65% relapse rate [34]. Therefore current treatment regimens have been 
ineffective in reducing the relapse-rate of CRLF2 B-ALL. In addition, higher doses of 
chemotherapy have resulted in increased toxicity and side effects for patients [50-52]. 
Imatinib, when used in combination with standard therapy, increased survival of children 
with Ph+ B-ALL from ~35% to 80% [44, 53]. The  results  achieved  with  Imatinib’s  
ability to target the kinase in Ph+ B-ALL was ground breaking and provided a model that 
can be followed in order to identify therapies to treat CRLF2 B-ALL. The studies 
outlined in this dissertation are significant in that they identified therapeutic candidates 
that exhibited efficacy on CRLF2 B-ALL and other high-risk B-ALL by targeting 
molecular mediators of the CRLF2 signaling pathway and cellular processes. These drug 
candidates show promise and have the potential to be used in combination with standard 
therapy to increase efficacy of treatment for CRLF2 B-ALL. 
 
Scientific Approach 
Rationale 
Studies in high-risk B-ALL including CRLF2 B-ALL, which were conducted by 
Children Oncology Groups (COGs), have been directed towards genetic screening to 
identify high-risk patients using risk stratification schemes [33, 38]. Additional studies 
were conducted to assess CRLF2 B-ALL patient response to current treatment options 
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and to determine therapeutic outcome, but very little is known about the cellular and 
molecular mechanisms that contribute to the progression of the disease [34, 54]. Recent 
molecular studies have shown that in some cases CRLF2 is associated with activating 
mutations in JAKs that act downstream of TSLP-CRLF2 interactions. These activating 
mutations have been shown to promote constitutive dimerization, constitutive JAK-STAT 
activation and cytokine independent growth in the murine BAF3 cellular model system 
[42, 55]. These data have led others to the conclusion that over-expression of CRLF2 and 
activating JAK mutations are the major contributors to this disease suggesting that 
CRLF2 B-ALL cells do not require TSLP-induced signals for survival and proliferation 
due to constitutive activation of the JAK-STAT pathway. However, all JAK mutations 
are not activating and 30% of CRLF2 B-ALL patients have no mutations in JAKs. 
Our lab and others have shown that TSLP induces proliferation of normal human 
B-cell precursors via activation of JAK-STAT or mTOR pathways [20, 24][TM unpub 
data]. In addition, our lab has demonstrated that TSLP is produced by bone marrow 
stromal cells and thus is present in the BM microenvironment where leukemia develops 
[TM unpub data]. Our lab also showed that TSLP increases STAT5 phosphorylation in 
CRLF2 B-ALL. These data provided a rationale for evaluating the role of the TSLP-
induced CRLF2 signaling in the development and/or maintenance of CRLF2 B-ALL. Not 
long after, Tasian, et al showed that stimulating primary CRLF2 B-ALL cells resulted in 
what  they  termed  as  “aberrant”  activation  of  JAT-STAT and PI3K/mTOR signaling [25]. 
Further their studies confirmed that TSLP can indeed stimulate CRLF2 B-ALL cells with 
or without JAK mutations thereby strengthening our rationale for conducting TSLP-
induced studies. Additionally, in vivo studies to evaluate the efficacy of treatments for 
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CRLF2 B-ALL are conducted in context of the presence or absence of JAK-mutations 
and without TSLP-induced CRLF2 signals [56]. Thus, the contributions of TSLP (the 
ligand that stimulates CRLF2 signaling) to the development, maintenance and/or 
progression of CRLF2 B-ALL and the cellular and molecular mediators involved remain 
to be fully elucidated. Therefore the objective of my dissertation studies was to elucidate 
the TSLP-induced cellular and molecular mechanisms that contribute to CRLF2 B-ALL 
and to identify promising drug candidates to target this disease.  
Based on findings from the literature and data obtained from our lab, we 
hypothesized that TSLP contributes to CRLF2 B-ALL by increasing proliferation and/or 
survival of leukemia cells via regulation of genes downstream of TSLP-CRLF2 pathway 
activation. The hypothesis was tested conducting experiments according to three specific 
aims and their respective sub-aims. Aim 1: Optimize the novel hTSLP+/- xenograft 
model for use in defining the role of TSLP in CRLF2 B-ALL. Aim 1.1 Engineer 
immune deficient mice to express human TSLP; Aim 1.2 determine whether CRLF2 
pathways are activated in vivo in hTSLP+ mice. In Aim 2: Identify TSLP-induced 
cellular and molecular mechanisms that contribute to CRLF2 B-ALL. Aim 2.1 
compare apoptosis status of CRLF2 B-ALL cells from hTSLP+ and hTSLP- mice; Aim 
2.2 identify pro-survival genes that are regulated by TSLP. Aim 3: Assess candidate 
drugs’  efficacy  against  high-risk B-ALL. Aim 3.1 evaluate candidate cancer drugs for 
in vitro efficacy in high-risk B-ALL; Aim 3.2 use the human-mouse xenograft model to 
evaluate the in vivo efficacy of candidate drugs in high-risk B-ALL. 
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Innovation 
A Novel In-vivo Model to Identify TSLP-induced Molecular Mediators in CRLF2  
B-ALL 
Preliminary data from our lab shows that pediatric BM stromal cells express the 
TSLP growth factor and thus provide an in vivo source of TSLP to stimulate CRLF2 B-
ALL cells [TM unpub data]. Therefore it is important that in vivo studies to evaluate 
therapies for CRLF2 B-ALL be performed in an in vivo model that includes TSLP, which 
can stimulate activation of the CRLF2 signaling pathway in these cells. Human-mouse 
xenograft models produced by injecting human leukemia cells into immune deficient 
mice are the in vivo models of choice for identifying effective chemotherapies to treat 
leukemia [57-58]. These models are possible because many growth factors and cytokines 
produced in the mouse act on human cells. However, mouse TSLP does not stimulate 
human CRLF2 [59]. Therefore standard xenograft models are inadequate for evaluating 
the role of TSLP-induced signaling and downstream molecular mediators in CRLF2 B-
ALL. Our lab has modified the human-mouse xenograft model currently used by other 
researchers to produce a novel human TSLP+/– xenograft model system composed of 
mice that express human TSLP (hTSLP+) or mice without human TSLP (hTSLP–) [60]. 
Studies shown in this dissertation include xenograft mice that were transplanted with 
primary CRLF2 B-ALL cells taken from patient samples collected at the Loma Linda 
University Medical Center (LLUMC) through collaboration with the Pediatric Oncology 
Group (POG). These studies are innovative in that they are the first studies in which 
human leukemia cells harvested from hTSLP+/hTSLP- xenograft mice were used to 
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identify TSLP-induced in vivo cellular processes and molecular mediators in CRLF2 B-
ALL. 
 
New Therapeutics to Target the CRLF2-Signaling Pathway 
CRLF2 B-ALL patients experience a high rate of relapse with current therapies. 
We have ongoing collaborations with internal and external research groups that have 
synthesized novel compounds to test for the treatment of high-risk B-ALL, including 
CRLF2 B-ALL. Candidate drugs included the following: 1) Novomedix (NM) lead series 
drugs: a series of small molecule drugs that have been shown to target cell cycle and 
protein translation functions in cells; 2) Mcl-1 inhibitor: a small molecule inhibitor that 
shows selective inhibition of the anti-apoptotic functions of the Bcl2 family member, 
Mcl-1 [62]. These studies are innovative in that they explore novel therapeutic candidates 
(in the case of the NM drugs) as well they utilize a novel approach of using known drug 
candidates (such as the Mcl-1 inhibitor) to identify potential therapeutic candidates to 
treat high-risk leukemia such CRLF2 B-ALL and Nalm6.  
 
Tools and Models 
CRLF2 B-ALL Cell Lines  
Human CRLF2 B-ALL cell lines were used to study the role of TSLP stimulation 
in CRLF2 B-ALL cells in vitro and in vivo as well as in drug efficacy studies. Cell lines 
are easy to culture, thus they are excellent tools for performing cellular and molecular in 
vitro studies. 
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Primary CRLF2 B-ALL Cells 
Even though cell lines are excellent tools, these cells may undergo changes over 
time, which may make them different from the original cells taken directly from a patient. 
Primary cells are difficult to culture and to manipulate, but they are the closest 
representation of the patient condition, thus it is important to study these cells. Therefore 
primary cells were also used to validate results. Primary cells were collected from 
collaborations with Hematology Oncologists in the LLUMC under approved IRB 
protocols.  
 
HTSLP+/HTSLP- Xenograft Samples  
Studies that assessed the effects of TSLP on CRLF2 B-ALL at the cellular and 
molecular levels were conducted using CRLF2 B-ALL cell lines or primary cells that 
were expanded in hTSLP+ and hTSLP- mice. These samples allowed us to compare 
proliferation, apoptosis, gene expression and protein expression of human CRLF2 B-ALL 
cells taken from an in vivo microenvironment containing human TSLP compared to those 
taken from mice without TSLP. 
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CHAPTER TWO 
A NOVEL XENOGRAFT MODEL TO STUDY THE ROLE OF TSLP-CRLF2 
SIGNALS IN NORMAL AND MALIGNANT HUMAN B-LYMPHOPOIESIS 
 
Abstract 
The cytokine, TSLP, stimulates in vitro proliferation of human fetal B cell 
progenitors, however, its in vivo role during normal human B lymphopoiesis is unknown. 
Genetic alterations that cause overexpression of the TSLP receptor component, CRLF2, 
lead to B cell acute lymphoblastic leukemia (CRLF2 B-ALL), implicating the TSLP-
CRLF2 pathway in leukemogenesis. Engineered cellular models suggest that mouse 
TSLP is unlikely to activate human CRLF2-mediated signals, limiting the utility of 
classic human-mouse xenografts for studies of the TSLP-CRLF2 pathway in normal and 
malignant B lymphopoiesis. First, we show that mouse TSLP does not induce activation 
of the CRLF2 downstream pathways (JAK/STAT5 and PI3K/AKT/mTOR) that are 
activated by human TSLP (hTSLP) in CRLF2 B-ALL cells. Next, we engineered 
xenograft mice to produce hTSLP (+T mice) by transplantation with stromal cells 
transduced to express hTSLP. Controls (–T mice) were produced by transplantation with 
stroma transduced with a control vector. Normal serum levels of hTSLP were achieved in 
+T mice, while hTSLP was undetectable in –T mice. hTSLP produced by +T stroma 
induced JAK/STAT5 and PI3K/AKT/mTOR pathway activation and showed functional 
in vivo effects on normal human B cell progenitors and primary CRLF2 B-ALL cells. 
Gene expression profiling of primary CRLF2 B-ALL cells showed an induction of 
mTOR regulated gene expression and increased TSLP-regulated gene responsiveness 
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when cells were expanded in +T as compared to –T mice. The novel +T/–T xenograft 
model developed here provides a tool for understanding the role of the TSLP-CRLF2 
pathway in normal and malignant hematopoiesis. 
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NSG    NOD/SCID Gamma (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) 
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Introduction 
TSLP plays key roles at several points in normal hematopoietic cell development 
and function, including early stages of B cell development (1-4). TSLP is an IL-7-like 
cytokine that can replace IL-7 in stimulating the expansion of murine B cell precursors 
(5, 6). The role of TSLP in the production of human B cells is less clear, although it has 
been shown to support the proliferation of human fetal B cell progenitors (7, 8). Genetic 
alterations that cause overexpression of a TSLP receptor component, CRLF2, have been 
linked to B cell acute lymphoblastic leukemia (B-ALL), thus implicating the TSLP 
pathway in leukemogenesis (9-12).  
B-ALL is the most common childhood malignancy (13-15) and despite advances 
in treatment strategies, ~25% of pediatric B-ALL patients relapse (16). Genomic 
profiling studies have identified several high-risk B-ALL subtypes that are resistant to 
chemotherapy (17-20). CRLF2 B-ALL is a high-risk subtype characterized by alterations 
of the CRLF2 gene leading to over-expression of the CRLF2 protein on the surface of B-
ALL cells (9-12). CRLF2 and the IL-7 receptor alpha chain (IL-7RD) together form a 
cytokine receptor signaling complex that is activated by TSLP (Figure 2.1) (6, 21). 
Binding of TSLP induces CRLF2 to dimerize with the IL-
activation of the JAK-STAT5 pathway (22, 23) as well as the PI3K/AKT/mTOR pathway 
(24, 25). The finding that JAK kinases are mutated in CRLF2 B-ALL (26) suggested that 
CRLF2 and mutated JAK cooperate to induce constitutive STAT5 activation in CRLF2 
B-ALL (27, 28). However, approximately half of CRLF2 B-ALL lack JAK mutations. 
Thus, the role of TSLP in CRLF2 B-ALL remains unclear. 
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Fig. 2.1: Pathways activated downstream of TSLP receptor signaling in human cells. 
 
 
 
Patient-derived xenograft (PDX) models produced by injecting human cells into 
immune deficient mice provide in vivo preclinical models for understanding disease 
mechanisms and identifying effective therapies. However, the available data (6) suggests 
that TSLP produced in the mouse (mTSLP) is unlikely to stimulate CRLF2-mediated 
signaling in human cells. Given the role of TSLP in activating the CRLF2 pathway and 
the downstream proliferation of human B cell progenitors, it will be important that 
studies to identify disease mechanisms and potential therapies for CRLF2 B-ALL be 
performed in preclinical models that provide human TSLP (hTSLP).  
Here we describe the development of a novel xenograft model system comprised 
of mice that provide hTSLP (+T mice) and mice that do not (–T mice). +T xenograft 
mice show functional in vivo hTSLP effects, expanding the production of normal B 
lineage cells from hematopoietic stem cells and inducing changes in mTOR-regulated 
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gene expression in primary CRLF2 B-ALL cells. The +T/–T xenograft model system 
provides an important new model for understanding the role of TSLP in normal and 
malignant B lymphopoiesis.  
 
Materials and Methods 
Human Samples and Cell Lines 
Human CRLF2 B-ALL cell lines MUTZ5 and MHH-CALL4 were purchased 
from DSMZ (Braunschweig, Germany). The human stromal cell line HS27 was 
purchased from ATCC (Manassas, VA). Primary human CRLF2 B-ALL cells and 
umbilical cord blood (CB) were obtained in accordance with protocols approved by the 
Loma Linda University Institutional Review Board (IRB) and with the Helsinki 
Declaration of 1975, as revised in 2008. CD34+ cells were isolated from CB as described 
in companion paper. Culture media are described in the online supplementary methods. 
 
Mice 
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
(Jackson Laboratory). Mice were housed under pathogen-free conditions in the Loma 
Linda University Animal Care Facility and studies were conducted in accordance with 
Loma Linda University Institutional Animal Care and Use Committee (IACUC) 
approved protocols.  
 
Flow Cytometry 
Cells were prepared for flow cytometry to detect surface antigens using protocols 
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described in companion paper. Details of phospho-flow cytometry and specific antibody 
clones and conjugates are described in online supplementary methods. Flow cytometry 
analysis was performed using a MACSQuant analyzer (MiltenyiBiotec, Inc, Auburn, CA) 
and Flowjo flow cytometry data analysis software (TreeStar, Ashland, OR) 
 
Stromal Cell Transduction 
Human HS27 stromal cells were transduced to express hTSLP (+T stroma) or 
with control vector (–T stroma) at a multiplicity of infection of 0.5-5/cell overnight. After 
transduction, cells were washed, expanded in culture, and frozen in aliquots. For the 
generation of +T and –T mice, stromal cells were thawed, cultured, and injected into 
mice within 15 passages after thawing. Details of lentiviral vector production and 
ELISAs to determine hTSLP levels are available in online supplementary methods. 
 
Xenograft Transplantation 
HS27 stroma that were transduced to be +T or –T were injected intraperitoneally 
into NSG mice at doses of 5 or 10x106 cells at time points described in the results section. 
Mice were sub-lethally irradiated with 225 cGy, then transplanted by tail vein injection 
with freshly thawed human umbilical cord blood CD34+ cells (1x105) or primary CRLF2 
B-ALL (5x105) cells.  
 
Microarray Analysis of Gene Expression in CRLF2 B-ALL Cells 
Microarray analysis of gene expression in patient-derived CRLF2 B-ALL cells 
following TSLP stimulation in vivo and ex vivo were  performed  by  Miltenyi  Biotec’s  
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Genomic Services (Miltenyi Biotec GmbH, Bergisch Gladbach) using Agilent Whole 
Human Genome Oligo Microarrays (Design ID 039494, 8x60K v2). Gene Set 
Enrichment Analysis (GSEA) was performed by Novogenix Laboratories, LLC (Los 
Angeles, CA). Details of microarray assays, data processing, differential gene expression 
analysis, GSEA, Ingenuity Pathway Analysis (IPA) and quantitative RT-PCR analysis are 
described in the online supplementary methods. The data discussed in this publication 
have been deposited in NCBI's Gene Expression Omnibus (29) and are accessible 
through GEO Series accession number GSE65274 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE65274). 
 
Results 
Mouse TSLP does not Activate the Human TSLP Receptor Complex 
Activation of the human TSLP receptor complex can be induced by hTSLP, but 
not by mTSLP, in murine Ba/F3 cells transduced to express human CRLF2 and IL-7Rα  
(6). These data suggest that mTSLP is unlikely to activate human CRLF2-mediated 
signals in human-mouse xenograft models. However, the ability of mTSLP to activate 
CRLF2- signaling in human cells, particularly those expressing high levels of CRLF2 
observed in CRLF2 B-ALL, has not been reported. To determine if mTSLP can induce 
CRLF2-mediated signals we tested its ability to activate downstream pathways in human 
CRLF2 B-ALL cells. First, we verified that the CRLF2 B-ALL cell lines and primary 
CRLF2 B-ALL cells used in our studies express both of the TSLP receptor components. 
Expression of IL-7Rα,  as well as high levels of CRLF2, was observed in both CRLF2 B-
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ALL cell lines and in the primary CRLF2 B-ALL cells used in studies described here 
(Figure 2.2).  
 
 
Figure 2.2: CRLF2 B-ALL cell lines (MUTZ5, MHH-CALL4) and primary CRLF2 B-
ALL cells used to produce patient-derived xenografts (PDX) used in the studies described 
here were stained for flow cytometry to detect the TSLP receptor components (IL-7Rα  and  
CRLF2). Plotted are cells within living cell light scatter. Quadrants shown were set based 
on isotype controls. 
 
 
Next we used phospho-flow cytometry to determine whether mTSLP can activate 
the JAK-STAT5 and PI3K/AKT/mTOR pathways activated by hTSLP in CRLF2 B-ALL 
cells (30). Although hTSLP induced clear increases in phosphorylated STAT5 (pSTAT5) 
in CRLF2 B-ALL cell lines and primary CRLF2 B-ALL cells, mTSLP showed no effect 
(Figure 2.3).  
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Figure 2.3: CRLF2 B-ALL cell lines and CRLF2 B-ALL cells from a PDX generated from 
the primary cells in panel C were stimulated with human TSLP (hTSLP) and mouse TSLP 
(mTSLP) at 15ng/ml, or no cytokine and evaluated for phosphorylated STAT5 (pSTAT5) 
AKT (pAKT), and S6 (pS6) by intracellular phospho-flow cytometry.   
 
 
Stimulation of CRLF2 B-ALL cells with mTSLP also failed to increase 
phosphorylated AKT (pAKT), while hTSLP produced modest increases (Figure 2.3). The 
ribosomal protein S6 is phosphorylated downstream of mTOR activation (31) and a 
robust induction of phosphorylated S6 (pS6) was observed in CRLF2 B-ALL cells 
stimulated with hTSLP (Figure 2.3). In contrast, no increases in pS6 were observed when 
cells were stimulated with mTSLP (Figure 2.3). Taken together, these data show that 
mTSLP fails to induce the STAT5, AKT, or S6 phosphorylation that are characteristic of 
CRLF2-mediated signals induced by hTSLP in human CRLF2 B-ALL cells. Thus, TSLP 
produced in the mouse cannot induce human CRLF2-mediated signals in existing human-
mouse xenograft models. 
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Engineering Xenograft Mice to Express Normal Serum Levels of Human TSLP  
We developed a strategy for engineering xenograft mice that can provide hTSLP 
to activate CRLF2-mediated signals (Figure 2.4). Expression of human cytokines in 
xenograft mice has been achieved by transplanting mice with human stromal cells (32). 
Our strategy was to build on this approach and engineer immune deficient NSG mice that 
express stable, sustained serum levels of hTSLP similar to normal reported levels in 
children (range 13-32 pg/ml (33)). This would be achieved by intraperitoneal injection of 
stromal cells transduced to express high levels of hTSLP. Human HS27 stromal cells 
were transduced with lentiviral vector containing hTSLP (+T stroma) or with control 
vector (–T stroma).  
 
 
Figure 2.4: Strategy for developing the +/–hTSLP xenograft model: 1) HS27 stromal cells 
transduced with a lentiviral vector to express hTSLP (+T) or with empty vector control (–
T). 2) Transduced stroma intraperitoneally injected to produce +T and –T NSG mice. 3) 
Human cells injected to produce xenograft mice with hTSLP (+T xenograft mice) and 
without hTSLP (–T xenograft mice)  
 
 
Supernatant collected from stroma after multiple passages following the initial 
transduction with hTSLP was evaluated by ELISA and showed TSLP levels of ~500 
31 
pg/ml (Figure 2.5, transduction 1). The ability of +T stroma to generate measureable 
serum levels of TSLP in vivo was evaluated. NSG mice receiving weekly intraperitoneal 
injections of 5X106 +T stroma showed serum hTSLP levels that were low but detectable 
(4-10 pg/ml; data not shown) as measured by ELISA. To achieve higher levels of 
sustained hTSLP expression NSG mice were injected with 3 doses of 1X107 +T or –T 
stroma over a 1 week period (loading dose) followed by weekly injections of 1X107 
stromal cells. Serum was collected at weekly time points and hTSLP levels were 
evaluated by ELISA. The initial 3 doses of stroma gave serum TSLP levels that were ~80 
pg/ml which quickly dropped to 15-20 pg/ml with weekly injections of +T stroma (Figure 
2.6, transduction 1). hTSLP was not detectable in the sera of mice transplanted with –T 
stroma (Figure 2.6, transduction 1). These data show that +T stroma can generate normal 
serum levels of hTSLP and that serum levels of hTSLP correspond to the number of 
stromal cells injected during the previous one to two week period. Thus, the loading dose 
that allowed us to achieve normal serum levels resulted in an initial spike in hTSLP 
rather than stable sustained levels of serum hTSLP that we had hoped to achieve. These 
data suggested that stable, sustained TSLP production might be more likely with weekly 
injections of stroma that could deliver slightly higher doses of TSLP. 
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Figure 2.5: Culture supernatant from HS27 +T and HS27 –T stromal cells was assessed by 
ELISA to determine levels of hTSLP protein produced by HS27 cells from transduction 1 
(+T only). Supernatant from transduction 2 was collected at early (passage 1-5), mid 
(passages 6-10) and late (passages 11-15) post thaw passages and hTSLP levels were 
evaluated by ELISA.  
 
 
Figure 2.6: Serum levels of hTSLP in blood collected at indicated time points from +T or 
–T mice injected with stroma as determined by ELISA were as follows: C) loading dose (3 
doses of 1X107 in first week) followed by weekly doses of 1X107 stromal cells 
(transduction 1 cells), graphed are the means ± SEM of n = 2-7 mice at each time point. D) 
injection of 5X106 stromal cells (transduction 2) at weekly intervals; graphed are the means 
± SEM n ≥  24  mice  at  each  time  point.   
 
 
 
A second stromal cell transduction was performed. Supernatant was collected at 
each passage for evaluation of hTSLP protein expression by ELISA. Stable production of 
hTSLP averaging ~900 pg/ml was observed at early, mid and late passages in +T stroma 
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across multiple thaws of frozen aliquots from the second transduction (Figure 2.5, 
transduction 2). hTSLP was undetectable in supernatant from similarly passaged –T 
stroma (Figure 2.5, transduction 2). NSG mice transplanted at weekly time points with 
5X106 stroma from transduction 2 showed serum hTSLP levels of approximately 20 
pg/ml that were stable up to 11 weeks (Figure 2.6, transduction 2 and data not shown). To 
verify that the hTSLP produced in our model induces CRLF2-mediated signals, we 
assessed CRLF2 B-ALL cell lines for activation of the JAK/STAT5 and 
PI3K/AKT/mTOR pathways by phospho-flow cytometry. Supernatant from +T stroma 
induced robust pSTAT5 and pS6 and minimal pAKT (Figure 2.7). In contrast, CRLF2 B-
ALL cells stimulated with supernatant from –T stroma showed background levels of 
pSTAT5, pAKT, and pS6, similar to levels observed in cells incubated with medium 
alone (Figure 2.7). These data show that +T stroma, but not –T stroma used in our model 
produce hTSLP that can activate signaling in human CRLF2 B-ALL cells.   
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Figure 2.7: CRLF2 B-ALL cell lines were stimulated with stromal cell supernatant and 
levels of pSTAT5, pAKT and pS6 were measured by intracellular phospho-flow cytometry. 
 
 
HTSLP Produced in Xenograft Mice Shows Functional Effects on Normal Human  
B-lineage Cells  
Next we evaluated the ability of hTSLP in +T mice to induce functional effects in 
human B lineage cells in vivo. Normal B cell precursors respond to direct stimulation by 
TSLP ((4) and companion paper, Figure 1), despite their low levels of CRLF2 expression 
((4) and Figure S1-Appdx A), and thus provide a sensitive in vivo functional test of the 
hTSLP produced in our xenograft model. To test our xenograft model we compared 
normal B cell production in +T and –T NSG mice transplanted with umbilical CB CD34+ 
cells followed by weekly injections of +T and –T stroma (Figure 2.8A). Five weeks post-
transplant mice were euthanized and bone marrow (BM) was harvested for flow 
cytometry to evaluate the production of B lineage and other hematopoietic cells. Mouse 
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and human cells were identified based on expression of mouse CD45 (mCD45) and 
human CD45 (hCD45) respectively (Figure 2.8B). Levels of human cell engraftment 
were high (>90%) in +T and –T animals, consistent with what we have previously 
observed in NSG mice transplanted with CB CD34+ cells (Su, unpublished data).   
 
 
 
 
Figure 2.8 A-C: hTSLP produced in +T xenograft mice shows functional effects on normal 
human B lineage cells. A) –T and +T NSG mice were transplanted with 1 X 105 CD34+ 
human cord blood (CB) cells and injected with weekly doses of 1X107 stromal cells. B) 
Five weeks post-transplant, mice were euthanized, BM harvested and cells were stained 
for flow cytometry to detect mouse CD45 (mCD45), human CD45 (hCD45), and hCD19. 
Total living cells were gated mCD45 vs. hCD45 is plotted with gates to identify mouse and 
human leukocytes respectively, in the BM. C) hCD45+ cells were gated and hCD19 
expression is shown by histogram. Percents are mean + SEM.  
 
 
 
TSLP has been shown to increase the in vitro production of human B cells ((4) 
and companion paper). To determine if hTSLP levels achieved in vivo in +T mice could 
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exert functional effects on normal human B lineage cells we compared the production of 
hCD19+ B lineage cells in the BM of +T and –T mice. Flow cytometry analysis of 
hCD19 expression on gated human (mCD45–hCD45+) cells showed that the percentage 
of B lineage cells was almost double in +T as compared to –T xenograft mice (Figure 
2.8C). A comparison of cell numbers in the BM showed that the number of B cells in +T 
mice was 3-4 fold that observed in the –T animals. This increase was not due to a global 
increase in hematopoiesis, but rather a selective increase in B cell production, since the 
number of hCD19– cells in the BM was slightly less in +T as compared to –T xenograft 
mice (Figure 2.8D). These data show that hTSLP produced in vivo in +T animals has a 
functional effect on normal human B lineage cells that express low levels of CRLF2.    
 
 
Figure 2.8D: Graphed are the average numbers of non-B lineage (hCD19–) and B lineage 
(hCD19+) cells isolated from the BM (2 tibia plus 2 femurs) of –T and +T mice as 
determined by hemocytometer count and flow cytometry (n=3 –T mice and n=5 +T mice). 
Statistical significance was calculated using a 2-tailed, unpaired t-test  (**  p≤  0.01;;  ***  P  
≤0.001).   
 
 
HTSLP in Xenograft Mice Induces MTOR-regulated Genes in Primary CRLF2 B-ALL  
Our next question was whether hTSLP in the +T animals induces gene expression 
profiles associated with pathway activation downstream of CRLF2-mediated signaling in 
primary CRLF2 B-ALL cells. NSG mice for these studies were injected with +T stroma 
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from transduction 1 and without a loading dose of stroma (Figure 2.9A). Serum levels of 
hTSLP produced in these mice were detectable but below normal levels (4-10 pg/ml) and 
therefore provide a sensitive test of hTSLP activity in +T mice.   
 
 
 
Figure 2.9 A-B: A) –T and +T NSG mice were transplanted with primary CRLF2 B-ALL 
cells and injected weekly with 5X106 stromal cells. B) 9 weeks post-transplant, mice were 
euthanized, BM was harvested and cells were stained with mCD45 and hCD19 to identify 
human B-ALL cells. CRLF2 staining on gated hCD19+ cells is shown in bottom panels.  
 
 
First, we evaluated the ability of NSG mice transplanted with HS27 stroma to 
support engraftment of primary B-ALL cells. +T and –T NSG mice were transplanted 
with primary cells (Figure 2.9B) aspirated from the BM of a Hispanic pediatric patient 
with CRLF2 B-ALL. Animals were euthanized at 9 weeks when peripheral blood 
chimerism reached 80%. BM was harvested and stained for mCD45 and human-specific 
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markers (CRLF2 and CD19) to identify CRLF2 B-ALL cells (Figure 2.9B). Flow 
cytometry analysis showed BM chimerism of human CRLF2 B-ALL cells was >90% in 
BM from both +T and –T mice (Figure 2.9B). These data show that NSG mice injected 
with –T and with +T stroma support engraftment of primary B-ALL cells.  
Next we compared gene expression in primary CRLF2 B-ALL cells from +T and 
–T mice using whole human genome oligo microarrays. Human CRLF2 B-ALL cells 
were isolated from the BM of +T and –T mice by magnetic separation and whole genome 
microarray was performed in triplicate using the Agilent platform. Differential gene 
expression analysis identified 280 gene reporters that were upregulated and 281 gene 
reporters that were downregulated at least 2 fold (Figure 2.9C). Microarray was validated 
by quantitative RT-PCR (qRT-PCR) analysis of selected differentially expressed genes 
(Table 5). Changes in gene expression by microarray and qRT-PCR were strongly 
correlated as indicated by linear regression (Figure 2.9D). 
 
 
 
Figure 2.9 C-D: C) Human hCD19+ B-ALL cells were isolated by magnetic separation and 
analyzed using whole genome microarray to identify genes that are differentially regulated 
in +T as compared to –T mice. Graphed are the number of Agilent gene reporters up or 
down-regulated  (≥2  fold,  p≤  .05)  in  CRLF2  B-ALL cells from +T as compared to –T mice. 
D) qRT-PCR validation of whole genome microarray. Regression analysis of fold changes 
measured by microarray versus fold changes measured by qRT-PCR.  
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GSEA (34, 35) was used to determine whether pathways induced by TSLP were 
activated in CRLF2 B-ALL cells from +T as compared to –T xenograft mice. GSEA of 
whole genome microarray data showed a strong enrichment (FDR q-value = 0.022) for 
genes regulated downstream of mTOR activation in CRLF2 B-ALL cells from +T 
animals as compared to –T animals (Figure 2.9E and Table 6).  
 
 
Figure 2.9E: Gene Set Enrichment Analysis (GSEA) of whole genome microarray data 
showed that CRLF2 B-ALL cells harvested from +T mice evidenced an increase in 
expression of genes regulated downstream of mTOR signaling as compared to cells from 
–T mice. The top half of the GSEA enrichment plot shows the enrichment score for each 
gene and the bottom half shows the values of the ranking metric moving down the list of 
the ranked genes.  
 
IPA of microarray data was used to identify the most significantly regulated 
canonical pathways in CRLF2 B-ALL cells from +T as compared to –T xenograft mice 
(Figure 2.9F). IPA showed that the mTOR pathway, as well as associated pathways (EIF2 
Signaling; Regulation of eIF4 and p70S6K Signaling) are among pathways significantly 
regulated in CRLF2 B-ALL cells from +T as compared to –T mice.  
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Figure 2.9F: Ingenuity Pathway Analysis (IPA) was performed based on gene reporters 
that were significantly up or down-regulated  (1.7  fold,  p≤0.05).  Graphed  are  the  canonical  
pathways significantly enriched in samples taken from +T as compared to –T mice. 
 
 
Taken together, GSEA and IPA analysis of gene expression data obtained from 
CRLF2 B-ALL cells show that mTOR signaling is up-regulated in +T as compared to –T 
xenograft mice. These data provide evidence that the hTSLP in +T mice, even when 
present at low levels, acts on CRLF2 B-ALL cells to increase mTOR pathway activation 
downstream of CRLF2. These data validate the use of +T/–T xenograft mice as a model 
system for studies to understand the role of TSLP in normal B cell production and in the 
development and progression of CRLF2 B-ALL.    
 
TSLP Responsiveness is Reduced in Primary CRLF2 B-ALL Cells Expanded in 
Xenografts Without HTSLP 
 TSLP is normally expressed by human BM stroma cells (see companion paper), 
thus, TSLP-mediated CRLF2 signaling is likely to be present during the initiation and 
TSLP-induced Canonical Pathways  
In  +T  vs.  –T  Xenografts  
 
F 
6.0 
5.0 
2.0 
1.0 
0.0 
3.0 
4.0 
7.0 
0.00 
0.10 
0.20 
0.30 
0.05 
0.15 
0.25 
–L
og
 (p
-v
alu
e)
 
Ratio 
Ox
ida
tiv
e  
Ph
os
ph
ory
lat
ion
 
EI
F2
 S
ign
ali
ng
 
mT
OR
 S
ign
ali
ng
 
Re
gu
lat
ion
 of
  
eIF
4 &
 p7
0S
5K
 
Mi
toc
ho
nd
ria
l  
Dy
sfu
nc
tio
n 
Se
rin
e &
 G
lyc
ine
  
Bio
sy
nth
es
is 
I 
My
c M
ed
iat
ed
  
Ap
op
tos
is 
ST
AT
3 P
ath
wa
y 
Fo
lat
e  
Tra
ns
for
ma
tio
ns
 I 
14
-3-
3-M
ed
iat
ed
  
Sig
na
lin
g 
0.35 
41 
progression of CRLF2 B-ALL. PDX samples used for studies of CRLF2 B-ALL are 
expanded in xenograft mice that lack the hTSLP required to activate CRLF2-mediated 
signals. Thus, it is important to determine whether the production of CRLF2 B-ALL PDX 
samples in xenograft mice that lack hTSLP can affect the subsequent response of these 
cells to TSLP. To address this question, we compared the ex vivo TSLP responses of 
CRLF2 B-ALL PDX samples generated in –T mice (–T PDX) to those generated in +T 
mice (+T PDX) by evaluating downstream changes in gene expression (Figure 2.10A).   
 
 
Figure 2.10A: TSLP responsiveness is reduced in primary CRLF2 B-ALL cells expanded 
in xenografts without hTSLP. A) BM from the –T and +T patient-dervied xenografts 
(PDX) generated from primary CRLF2 B-ALL cells as described in Figure 4 were 
stimulated with or without TSLP ex vivo for 3 days. Cells were harvested and hCD19+ 
cells were isolated by magnetic separation and assessed using whole genome microarray.  
 
 
BM harvested from the –T and +T PDX generated from primary CRLF2 B-ALL 
cells (Figure 2.9) was cultured ex vivo with and without TSLP (Figure 2.10A). After 3 
days of culture, cells were harvested and CRLF2 B-ALL cells were isolated by magnetic 
separation for whole genome microarray using the Agilent platform. Differential gene 
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expression analysis showed that 1632 gene reporters were up-regulated and 1754 gene 
reporters were down-regulated  (fold  change  ≥  2.0;;  p≤0.05)  when  +T  PDX  were  
stimulated ex vivo with TSLP (Figure 7B). In contrast, the number of gene reporters 
differentially regulated by TSLP was reduced by almost half (844 up-regulated and 914 
down-regulated) in –T PDX (Figure 2.10B). These data suggest that primary CRLF2 B-
ALL cells expanded in the absence of hTSLP have a reduced TSLP response with respect 
to TSLP-regulated gene expression.   
 
 
 
Figure 2.10B-D: B) Graphed are the number of Agilent gene reporters that are up- or down-
regulated  (≥2  fold,  p≤  0.05)   in  –T PDX (white) and +T PDX (black) following ex vivo 
stimulation by TSLP. C-D) Overlap (grey) between up- and down-regulated gene reporters 
in –T PDX (white) or +T PDX (black) following ex vivo stimulation by TSLP 
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as those in +T PDX. We examined the total gene reporters differentially regulated in 
CRLF2 B-ALL cells, regardless of whether cells were expanded in +T or –T animals 
(1814 total up-regulated and 1945 total down-regulated gene reporters) (Figure 2.10C-D). 
Of the total gene reporters regulated by TSLP, approximately half were up- or down-
regulated in +T PDX, but not in –T PDX. Conversely, 10% of gene reporters were up or 
down-related in –T PDX but not +T PDX. A little more than a third of gene reporters 
were regulated by TSLP in both –T and +T PDX. While the gene sets up and down-
regulated by ex vivo TSLP stimulation were only partially overlapping, it is important to 
note that no genes were oppositely regulated in +T and –T PDX samples.  
Taken together these data suggest that primary CRLF2 B-ALL cells expanded in 
xenograft mice without hTSLP show a reduced capacity to respond to TSLP as indicated 
by a reduction in TSLP-induced changes in gene expression.   
 
Discussion 
Human-mouse xenografts provide a critical complement to other models in 
understanding normal and malignant human B lymphopoiesis in context of the broad 
background of human genetic variation. A limitation of these models is the lack of cross-
species activity observed for some cytokines. Here we show that mTSLP does not induce 
the increases in STAT5 and PI3K/AKT/mTOR phosphorylation induced by hTSLP in 
CRLF2 B-ALL cells (Figure 2.3). CRLF2 B-ALL cells express abundant IL-7Rα  and  
CRLF2 as compared to normal B cell precursors (Figure 2.2 and Figure S1-Appdx A) 
and thus provide a sensitive test for mTSLP activity. These data establish that the classic 
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mouse xenograft models do not provide cross-species activation of the human TSLP 
receptor.    
We developed a strategy to overcome the lack of mTSLP cross-species activity 
while providing a +/– hTSLP (+T/–T) xenograft model system for studying the in vivo 
role of TSLP in normal and malignant hematopoiesis. NSG mice were engineered to 
express normal serum levels of hTSLP by intraperitoneal injection with stroma that had 
been transduced to express hTSLP (+T mice) or transduced with a control vector (–T 
mice). hTSLP produced in HS27 +T stroma induced STAT5 and PI3K/AKT/mTOR 
pathway activation and exerted in vivo functional effects on primary CRLF2 B-ALL cells 
(Figure 2.7) as well as normal B cell precursors (see Figure 2.8 and for a detailed analysis 
see companion paper). Further, we found that primary CRLF2 B-ALL expanded in –T 
mice showed a loss of TSLP responsiveness, as measured by TSLP-induced gene 
regulation, when compared to cells from the same patient expanded in +T mice (Figure 
2.10). The studies described here establish and validate a novel hTSLP+/– xenograft 
model system while providing the first data on the in vivo impact of TSLP in normal 
human B cell development and on primary CRLF2+ B-ALL cells. 
Normal serum levels of hTSLP were achieved in our model, however, a novel 
aspect of our model is the ability to modulate serum levels of hTSLP based on the timing 
and number of injected stromal cells. The ability to vary hTSLP levels or to initiate 
stromal cell injection (and TSLP production) at time points after transplantation offers 
advantages for experimental design. A potential limitation of our model is that the hTSLP 
is not produced directly from stroma in the BM. Although human BM stroma do produce 
TSLP (see companion paper), the cells believed to produce the most hTSLP–a range of 
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immune cells, smooth muscle cells, gut and skin epithelial cells (36)–reside outside the 
BM. Thus, the major source of TSLP that acts on normal and malignant B cells in vivo in 
patients may be produced outside the marrow as it is in our model. The ability to 
modulate serum levels of TSLP is also biologically relevant because TSLP production is 
increased by environmental factors such as pollutants and allergens and is up-regulated in 
some autoimmune diseases and solid tumors (37) making this model relevant to studies in 
these fields. 
CRLF2 B-ALL is five times more prevalent in Hispanic and Native American 
children than in others and is associated with poor outcome (26). CRLF2 B-ALL also 
comprises more than 50% of B-ALL in children with Down syndrome (10, 17, 38). 
Studies of the relationship between inherited genetic variation and susceptibility to ALL 
provide some clues to the relationship of ALL to ethnicity (39). However, little is known 
about cellular mechanisms that contribute to the initiation, progression and maintenance 
of CRLF2 B-ALL or the biological factors that contribute to the health disparities 
associated with this disease. Patient-derived xenograft (PDX) models are particularly 
critical for health disparities diseases where inherited genetic variation or alterations such 
as Down syndrome are likely to play a role in disease progression (40, 41). The primary 
CRLF2 B-ALL sample used to develop the model described here was obtained from a 
Hispanic pediatric patient. This PDX together with additional ones currently being 
generated with the +T/–T xenograft model will allow us to study disease mechanisms 1) 
in context of a genetic background associated with CRLF2 B-ALL health disparities and 
2) in context of TSLP-CRLF2 mediated signals present in vivo in the patient. 
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The model developed here provides an important new tool for understanding the 
mechanisms of TSLP activity in normal and malignant B lymphopoiesis. It also provides 
a preclinical model for identifying therapies to effectively treat CRLF2 B-ALL in an 
environment that can induce the TSLP-mediated signals present in vivo in patients and in 
context of the genetic background that leads to health disparities in this disease.   
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CHAPTER THREE 
TSLP EXERTS EFFECTS THAT ARE DISTINCT FROM IL-7 DURING  
NORMAL B-CELL DEVELOPMENT  
 
Abstract 
 
The role of TSLP in human B cell development is largely unknown and its 
function in context of IL-7 has not been studied. We found that TSLP can replace IL-7 in 
providing a signal essential for in vitro production and proliferation of human 
CD19+Pax-5+ B cell progenitors. To study the role of TSLP in human B cell 
development, in the context of IL-7 stimulation, we developed a novel xenograft model. 
Mouse IL-7 is active on human cells; however, this is not the case for TSLP. We took 
advantage of this to develop a xenograft model system comprised of mice that provide 
human TSLP (+T mice) and control mice that do not (–T mice). Using this model we 
found that TSLP increases proliferation and up-regulates Mcl-1 in CD19–CD34+IL7RD+  
progenitors resulting in a 3-4-fold expansion of the CD34+ pro-B cell compartment in +T 
as compared to –T mice. This expansion is maintained during subsequent stages of B cell 
development, partially due to increased protection from apoptosis that occurs 
independently of Bcl-2 family pro-survival proteins. TSLP stimulated in vitro 
proliferation of pro-B cells, however, in vivo proliferation of B lineage precursors was 
similar in +T and –T mice suggesting redundancy with IL-7. B cell subsets in normal 
pediatric BM samples show progenitor ratios and Mcl-1 expression that mirrors that in 
+T xenograft mice. These data provide evidence that TSLP function in human B 
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lymphopoiesis includes both unique activities as well as activities redundant to those of 
IL-7.  
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Introduction 
The roles of TSLP and IL-7 in mouse B lymphopoiesis include overlapping and 
unique functions (1-5). In vitro studies of human B cell development show that TSLP 
acts on fetal B cell precursors to induce proliferation (6), while IL-7 provides a signal 
critical for the production and proliferation of non-fetal B lineage cells (7-9). The role of 
TSLP in human B cell development beyond the fetal period has not been studied. 
Furthermore, its role in context of IL-7 during normal in vivo B cell development is 
unknown. Aberrant signaling in both the TSLP (10) and IL-7 (11) pathways is linked to B 
cell acute lymphoblastic leukemia, underscoring the importance of understanding the role 
of these cytokines in human B lymphopoiesis.    
TSLP and IL-7 signal through distinct complexes comprised of the IL-7RD and 
homologous secondary chains (12). The secondary chain for the IL-7 receptor complex is 
the common gamma chain (Jc) (13), while the secondary chain of the TSLP receptor 
complex is CRLF2 (TSLPRE) (14, 15). Both cytokines induce STAT5 activation, 
however, TSLP acts through JAK2, while IL-7 effects are mediated through JAK3 (17). 
Additionally, in human B lineage cells, TSLP induces the PI3K/AKT/mTOR pathway 
activation (18), although available evidence suggests that this pathway is not activated by 
IL-7 (19). Thus, TSLP and IL-7 exhibit both shared and distinct receptor components as 
well as downstream signaling pathways. 
 IL-7R-mediated signals are likely to play different roles in mouse and human B 
cell development. In mice, IL-7 activates the PI3K/AKT pathway in B lineage cells, but 
this is not the case in humans (19). Furthermore, homologies in TSLP and in CRLF2, 
between the two species are very low (~40% protein level identity) (20, 21). This 
55 
contrasts with other cytokines and receptor components, including IL-7 and the IL-7RD 
which show ~70% homology between mouse and human. As a consequence, mouse 
TSLP does not show cross-species activity on human cells (14) and companion 
manuscript) while IL-7 does. This simultaneously highlights the importance of studying 
B cell development in human systems, while identifying a challenge of doing so: mouse 
TSLP does not activate the human TSLP receptor complex. Consequently, IL-7RD 
signaling in human B lineage cells generated in classic human-mouse xenografts, is 
activated exclusively by mouse IL-7.    
Here we use a novel human-mouse xenograft system that produces human TSLP, 
together with human-only in vitro cultures and primary patient samples, to identify the 
role of TSLP in human B cell development in vivo, in context of IL-7. 
 
Materials and Methods  
Human Samples 
Umbilical cord blood (CB) and bone marrow (BM) were obtained in accordance 
with protocols approved by the Loma Linda University Institutional Review Board (IRB) 
and with the Helsinki Declaration of 1975, as revised in 2008. CD34+ cells were isolated 
by magnetic separation with CD34+ microbeads (Miltenyi Biotec, Auburn, CA) from 
mononuclear cells. Detection of human TSLP production in BM stromal cells is 
described in online supplementary methods. 
 
Selective-Cytokine Co-cultures 
Human-only co-cultures were as described (9). Briefly, CB CD34+ hematopoietic 
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stem cells (HSC) cells were seeded on primary human BM stromal cells. Cultures were 
maintained in medium supplemented with 5% human AB serum (Omega Scientific, 
Tarzana, CA) lot tested to support human B cell production. All cultures, including 
control, were supplemented with IL-3 and Flt-3 Ligand. For selective cytokine 
stimulation, TSLP and/or IL-7 (R&D Systems Inc., Minneapolis, MN) were added. If 
TSLP and/or IL-7 were not added, cultures were further supplemented with an anti-
human neutralizing antibody to counter activity of endogenously produced TSLP and/or 
IL-7. Cultures without specific neutralizing antibody (anti-IL-7 and/or anti-TSLP) were 
supplemented with an isotype-matched control for the neutralizing antibody. Cultures 
were maintained for three weeks, and then harvested. For BrdU incorporation, co-cultures 
were labeled with 10 uM BrdU (Sigma-Aldrich, St. Louis, MO) for the final 24 hours of 
culture. 
 
Flow Cytometry 
Cells were prepared for flow cytometry to detect surface antigens according to 
manufacturer’s  protocols.  Details  of  intracellular  staining  and  specific  antibody  clones  
and conjugates are described in online supplemental methods. Flow cytometry analysis 
was performed using a MACSQuant analyzer (Miltenyi Biotec, Inc. Auburn, CA) and 
Flowjo data analysis software (TreeStar, Ashland, OR).   
 
Statistical Analysis 
Statistical analysis was performed using Students t test or one-way analysis of 
variation (ANOVA) and data expressed as mean ± SEM. Statistical significance was 
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defined as p<0.05. 
 
Animal Studies 
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
(Jackson Laboratory) under protocols approved by the Loma Linda University 
Institutional Animal Care and Use Committee (IACUC). Mice were engineered by 
intraperitoneal injection with stroma transduced to express human TSLP (+T mice) or 
stroma transduced with control vector (–T mice) as described in the companion paper. +T 
and –T mice were transplanted with 1"105 CD34+ cells by tail vein injection, after sub-
lethal irradiation at 225 cGy. Mice were euthanized 5-7 weeks after transplantation and 
tissues harvested and frozen for flow cytometry analysis.   
 
Results 
TSLP can Replace IL-7 in Supporting the In vitro Production and Proliferation of 
Human CD19+Pax-5+ B cell Progenitors 
To compare the effects of TSLP and IL-7 in early stages of human B cell 
production, we developed a human-only culture model that provides selective cytokine 
stimulation. Human CD34+ HSCs were cultured with primary human BM stromal cells 
in media supplemented with human serum. Selective cytokine stimulation was achieved 
by supplementing with combinations of exogenous IL-7 and/or TSLP and with 
neutralizing antibodies to counter activity of endogenously produced IL-7 and TSLP in 
cultures where cytokine is not added (Figure 3.1A). CB CD34+ HSCs were plated in 
human-only selective cytokine cultures to compare the production of B cell progenitors 
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under the influence of TSLP or IL-7 alone and in combination. Culture progeny were 
harvested and stained for flow cytometry to identify CD19+PAX-5+ B lineage cells. 
Control cultures that lacked TSLP or IL-7 showed little B cell production (Figure 3.1B). 
In contrast, TSLP, IL-7, and TSLP+IL-7 cultures showed robust production of 
CD19+PAX-5+ B lineage cells (Figure 3.1B). There was no significant difference in the 
numbers of B lineage cells produced in cultures with TSLP as compared to cultures with 
IL-7 (Figure 3.1C). Furthermore, there was no additive effect when cultures were 
supplemented with both cytokines.   
 
 
Figure 3.1 A-C: (A) Human-only cultures were produced by plating primary human CB 
CD34+ cells on primary BM stromal cells. Selective cytokine stimulation was achieved by 
supplementing cultures with exogenous IL-7 and/or TSLP or neutralizing antibodies to 
TSLP (anti-T) or IL-7 (anti-7) as indicated. Cultures without a particular neutralizing 
antibody were supplemented, as a control with non-specific isotype-matched antibodies 
(ctrl Ig). All culture conditions included IL-3 and Flt-3 ligand, two cytokines that support 
early lymphoid progenitors (35, 36). Cultures were maintained for three weeks, then 
harvested and stained for flow cytometry. (B) Dot plots showing CD19 vs. Pax5 staining 
in each culture condition are shown (representative of n=3 independent experiments). 
PAX-5 fluorescence minus one (FMO) control is displayed in inset. (C) Graphed are the 
relative numbers of CD19+ cells generated in vitro under indicated conditions at three 
weeks (n=14).  
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To determine if TSLP-induced proliferation contributes to the increased 
production of human B cell precursors from CB HSCs, we compared BrdU incorporation 
in cells generated under selective cytokine conditions (Figure 3.1D). Proliferation of B 
cell precursors was significantly increased in TSLP cultures as compared to control 
cultures without TSLP or IL-7 (Figure 3.1E). The percentage of BrdU+ cells in TSLP 
cultures was similar to that observed for cultures with IL-7 or TSLP+IL-7. Collectively, 
these data provide evidence that TSLP can replace IL-7 in providing signals that are 
critical for the in vitro production and proliferation of CD19+PAX-5+ B cell precursors. 
Further, the absence of additive effects observed in cultures with TSLP+IL-7 suggests 
that TSLP and IL-7 do not act on different populations of cells but rather a common set 
of B cell progenitors that can respond to either TSLP or IL-7. 
 
 
Figure 3.1D-E: (D) Representative dot plots of CD19 vs BrdU staining in indicated 
conditions. BrdU FMO control is displayed in the inset of the Ctrl dot plot. (E) Graphed is 
the percent BrdU+ cells (mean± SEM) in the total CD19+ population generated under 
indicated conditions at three weeks (n=8). Statistical analysis was performed using a one-
way ANOVA, with Dunnett multiple comparisons post test, *p<0.05,  **p<0.001.   
 
 
In vivo Human B cell Production in Xenografts With and Without Human TSLP 
The above data suggest that TSLP and IL-7 might provide redundant proliferative 
signals but do not address the potential for differential effects at specific stages during in 
vivo B cell development. We developed a novel xenograft model that allows us to study 
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in vivo stage-specific development of human B lineage cells in the presence and absence 
of TSLP. Unlike mouse IL-7, which can induce activation of the human IL-7R complex 
(8, 22, 23), mouse TSLP does not (see (21) and companion manuscript). We took 
advantage of this to develop a xenograft model system comprised of mice that provide 
human TSLP (+T mice) and control mice that do not (–T mice) (Figure 3.2A). The 
human TSLP in +T xenograft mice was active on normal human B lineage cells as 
indicated by the lineage-specific increases in CD19+ B lineage cells generated from CB 
CD34+ HSCs transplanted into +T as compared to –T mice (see chapter 2).   
 
 
 
Figure 3.2A-B: Xenograft model of human B cell development. (A) Immune deficient NSG 
mice were engineered by weekly intraperitoneal injection of stromal cells that were 
transduced either with empty vector (–T mice) or to express human TSLP (+T mice) as 
described in companion paper. CB CD34+ cells were injected by tail vein into –T and +T 
mice. Five weeks later BM was harvested and stained for flow cytometry to detect anti-
mouse CD45 (mCD45) and human-specific markers (B) to identify five developmentally 
sequential B cell subsets in the BM of –T and +T mice. IL-7R+ progenitors, a population 
of lymphoid-restricted multi-lineage progenitors (Su, unpublished data) were also 
identified. Gated subsets are shown for –T mice. 
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To distinguish in vivo, stage-specific effects of TSLP during human B cell 
development, we compared progenitor and B lineage subsets produced in mice that 
provide only IL-7 stimulation (–T mice) or both IL-7 and human TSLP stimulation (+T 
mice). Xenograft mice were engineered to be –T and +T and transplanted with CB 
CD34+ cells. Five weeks after transplantation, BM and spleens of mice were harvested 
and stained for flow cytometry to identify developmental subsets of human B lineage 
cells as well as IL-7R+ progenitors (Figure 3.2B). IL-7R+ progenitors are a population of 
CD19–CD34+ progenitors that represent the earliest hematopoietic progenitors capable 
of responding to TSLP and/or IL-7 based on their expression of IL-7RD. We found that 
all five B cell subsets, as well as IL-7R+ progenitors, were present in the BM of 
xenograft mice irrespective of the presence of human TSLP (Figure 3.2C-D). Similarly, 
spleens from –T and +T animals showed both immature and mature B cell subsets (data 
not shown).   
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Figure 3.2C-D: Gated subsets are shown for –T mice (C) and +T mice (D). The same gating 
strategy was used to identify immature and mature B cells in the spleens of the –T and +T 
mice.  
 
 
TSLP Alters the Distribution of Human CD34+ Progenitors in the BM of  
Xenograft Mice 
In vitro studies of human fetal B cell development show that CD34+ progenitor 
populations are responsive to TSLP (6). To determine whether TSLP effects on CD34+ 
populations are distinct from those of IL-7, we compared the distribution of CD34+ stem 
cell and progenitor populations in the BM of –T and +T mice.  Using gates shown in 
Figure 9C, D, we determined the distribution of total CD34+ cells from –T and +T 
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xenograft mice among three CD34+ subsets: HSCs/multi-lineage progenitors, IL-7R+ 
progenitors, and CD34+ pro-B cells.  The progenitors produced with IL-7 stimulation 
alone (–T xenograft mice) were distributed almost evenly between the three CD34+ 
subsets (Figure 3.3, left panel). In contrast, CD34+ progenitors produced with TSLP and 
IL-7 showed a skewing toward CD34+ pro-B cells which made up more than 75% of the 
entire CD34+ BM pool in + T mice (Figure 3.3, right panel). These data suggest that 
rather than inducing a global expansion of B lineage cells by amplifying IL-7R signals in 
a redundant fashion, TSLP exerts specific effects on CD34+ cells that are at least 
partially distinct from those of IL-7 during the early stages of human B cell 
differentiation from CD34+ CB HSCs.   
 
 
Figure 3.3: Distribution of total human CD34+ BM cells from –T and +T xenograft mice 
among three CD34+ subsets: HSCs/multi-lineage progenitors (CD19–CD34+IL-7R–), IL-
7R+ progenitors (IL-7R+), and CD34+ pro-B cells (CD19+CD34+), in BM of  –T mice 
and +T mice.  
 
 
TSLP Expands the Earliest CD19+ B lineage Committed Cells at the Expense of 
CD19–CD34+ cells that Express the IL-7RD
To gain insights into populations targeted uniquely by TSLP, we compared the 
absolute numbers of cells in developmental subsets produced in +T and –T mice. The 
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number of cells in the HSCs and multi-lineage progenitor compartment was similar in 
xenografts whether or not human TSLP was present. Surprisingly, in +T mice the number 
of IL-7RD+ progenitors was reduced. This contrasts with subsequent stages of B cell 
development, from CD34+ pro-B to mature B cells, where cell numbers were 
significantly increased in +T as compared to –T mice (Figure 3.4, left panel). Similarly, 
splenic numbers of immature and mature human B cells were increased in +T as 
compared to –T mice (Figure 3.4, right panel).  
 
 
Figure 3.4: Absolute number of cells in each progenitor and B lineage subset in the BM 
(left panel) and spleen (right panel) of –T (n= 3) and +T (n=5) xenograft mice. Statistical 
analysis was performed using a one-tailed, t-test, *p<0.05, **p<0.01 and ***p<0.0001. 
Error bars represent mean ± SEM.   
 
 
Taken together, these data show that TSLP alters the distribution of CD34+ 
progenitor populations, increasing the CD34+ pro-B compartment at the expense of IL-
7R+ progenitors. These data suggest that TSLP exerts unique stage-specific effects 
during early stages of B cell development. Furthermore, TSLP-induced increases in cell 
numbers early in the B lineage extend through all stages of B cell development in the BM 
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and spleen. These effects do no occur with IL-7 stimulation alone, suggesting that TSLP 
plays a role that is distinct from IL-7 in expanding the B cell progenitor compartment 
during in vivo human B lymphopoiesis. 
 
TSLP-induced Expansion of CD34+ Pro-B cells is Maintained, but not Augmented at 
Later Stages of In vivo B cell Development 
Because cells in early developmental subsets give rise to cells that progress to 
more mature stages of B cell development, the effect of TSLP on the most immature 
progenitors will result in increased cell numbers at each subsequent stage of 
development, independent of effects at more mature stages of development. To pinpoint 
stage-specific effects of TSLP-induced expansion, we graphed the fold change in cell 
numbers at each stage of B lineage development in +T mice relative to –T mice (Figure 
3.5, left panel).  
 
 
Figure 3.5: Graphed is the TSLP-induced fold change in the absolute number of progenitors 
and B lineage cells in the BM (left panel) and spleen (right panel) of +T as compared to –
T xenograft mice. Subsets were gated as described in Figure 2. Statistical analysis was 
performed using a one-way ANOVA, *p<0.05, **p<0.01 and ***p<0.001. Error bars 
represent mean± SEM.  
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The pool of HSC/multi-lineage progenitors was unchanged, but the IL-7R+ 
progenitor compartment was reduced in +T as compared to –T mice.  Despite its reduced 
size, the IL-7R+ progenitor population in +T xenograft mice gave rise to a CD34+ pro-B 
compartment that was more than 4-fold increased when compared to –T mice. As B cell 
development progressed, the ~4-fold increase was maintained until cells reached the 
mature B cell stage, where numbers in +T xenograft mice were only 2 fold that observed 
in –T mice. Similarly, the number of immature and mature splenic B cells (Figure 3.5, 
right panel), as well as the splenic weight (data not shown) in +T animals was ~2 fold 
that in –T xenograft mice. These data show that the overall increase in CD34+ pro-B cells 
that we observed in +T mice is largely maintained, but not further increased as B cell 
progenitors progress through each subsequent stage of development and migrate to the 
spleen.   
 
TSLP Increases Proliferation of IL-7R+ Progenitors but not CD19+ B lineage Cells 
To determine the cellular mechanism(s) responsible for increased in vivo B 
lineage production with TSLP stimulation, we first assessed proliferation based on Ki-67 
expression in developmental subsets. The IL-7R+ progenitors generated in +T animals 
showed increased Ki-67 expression (Figure 3.6, top panel). However, no differences in 
proliferation were observed in any of the subsequent committed B cell subsets derived 
from BM of the –T and +T mice.  
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Figure 3.6: Top panel: Expression of Ki-67 proliferation antigen in developmentally 
sequential progenitor B cell subsets in BM (left panel) and spleen (right panel). Bottom 
panel: Progenitor and precursor IgM– subsets were further separated based on IL-7RD, and 
Ki-67 expression as indicated by MFI is graphed for each subset in the  –T and  +T 
xenograft mice. Statistical analysis was performed using an unpaired one- tailed, t-test, 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Error bars represent mean ± SEM. 
Data shown are from –T mice (n = 3) and  +T mice (n=5). 
 
 
The IL-7RD chain is required for both IL-7 and TSLP-mediated signals. However, 
typically only ~20-50% of human pro-B and pre-B cells express IL-7RD (9) and it is 
undetectable by the immature stage of B cell development (Milford, unpublished data). 
To gain insights into the stage-specific roles of IL-7 and TSLP in the proliferation of B 
lineage committed progenitors, we compared Ki-67 expression in IL-7RD+ and IL-7RD– 
subsets from –T and +T xenograft mice (Figure 3.6, bottom panel). In both +T and –T 
mice, Ki-67 was significantly higher in the IL-7RD+ cells than in IL-7RD– cells in the 
pro-B and pre-B subsets.  
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 Taken together with data in Figures 8 and 9, these results suggest that TSLP 
increases proliferation of IL-7R+ progenitors and promotes up-regulation of PAX-5 
expression and differentiation to produce an expanded pool of differentiated 
CD34+CD19+ pro-B cells. They also provide evidence that IL-7 and TSLP act in a 
redundant manner to stimulate cycling of IL-7RD+ pro-B and pre-B cells.   
 
TSLP Protects Developing CD19+ B lineage Cells from Apoptosis 
Our next question was whether increased survival of B lineage cells might 
contribute to the increased pool of B lineage cells that we observed in +T xenograft mice. 
To address this question we evaluated apoptosis in IL-7R+ progenitors and B cell subsets 
by flow cytometry. Graphed in Figure 3.7 are the percentage of cells in each subset that 
were non-apoptotic as indicated by the absence of staining for the apoptotic markers, 
Annexin V and 7-AAD. Notably, the percentage of non-apoptotic cells was significantly 
higher in human pro-B, pre-B and immature B cells from +T as compared to –T mice. 
Similar percentages of non-apoptotic cells were observed among IL-7R+ progenitors and 
mature B cells (Figure 3.7) regardless of whether TSLP was present. Thus, during the 
development of CD19+ B lineage cells, TSLP has a unique pro-survival function that is 
not provided by IL-7.   
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Figure 3.7: Graphed are the percentages of non-apoptotic cells (Annexin V– 7-AAD– cells) 
in each subset from –T and +T mice. B) CD34+ progenitors along with B cell progenitor 
and precursor subsets were gated into IL-7RD– and IL-7RD+ fractions.  
 
 
TSLP-mediated Protection from Apoptosis is Independent of Bcl-2 Family Pro-survival 
Protein Expression 
To gain insights into the role of TSLP and IL-7 in the survival of developing B 
lineage cells and the contribution of Bcl-2 family pro-survival proteins in this process, we 
compared the expression of Bcl-2, Bcl-xL and Mcl-1 in IL-7R– and IL-7R+ cells within 
early progenitor and B cell precursors subsets. Expression of pro-survival molecules was 
first evaluated in B lineage cells produced in –T mice under the influence of IL-7 alone. 
With only IL-7, Bcl-2, Bcl-xL, and Mcl-1 were significantly increased in IL-7R+ as 
compared to IL-7R– cells in almost all subsets examined, from the most primitive IL-
7R+ progenitors through the pre-B cell stage (Figure 3.8 top panel). The exception was 
the marked absence of Mcl-1 up-regulation in IL-7R+ progenitors as compared to the 
HSC/multi-lineage progenitor population (CD19–CD34+IL-7R– cells). 
Next, we evaluated the expression of Bcl-2 family proteins during human B cell 
development in +T mice that provide TSLP in context of IL-7. When we compared IL-
7R– and IL-7R+ subsets from +T mice the pattern of Bcl-2, Bcl-xL, and Mcl-1 
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expression was almost identical to that observed in –T animals (Figure 3.8 top panel and 
Figure 3.8 bottom panel). However, in +T mice, we found that Mcl-1 expression was 
increased in the IL-7R+ progenitors as compared to their IL-7R– counterparts, which 
showed the same low level of Mcl-1 expression observed in all CD19–CD34+ cells in –T 
animals (bottom panel, far right). These data show that all three Bcl-2 family pro-survival 
proteins are up-regulated in human pro-B and pre-B cells that are IL-7R+ as compared to 
IL-7R– and that this up-regulation occurs whether or not TSLP is present. In contrast, 
TSLP exerts effects distinct from IL-7 to up-regulate Mcl-1 in human IL-7R+ 
progenitors.  
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Figure 3.8: Top panel: Graphed are the median fluorescence intensities (MFI) of (B) Bcl-
2, (C) Bcl-xL and (D) Mcl-1 in –T mice. Data are from n = 6 or 7 mice per group. Statistical 
analysis was performed using one-tailed, t-test, *p<0.05, **p<0.01 and ***p<0.001. Error 
bars represent mean ± SEM. Bottom panel: Graphed are the median fluorescence intensities 
(MFI) of (E) Bcl-2, (F) Bcl-xL and (G) Mcl-1 in +T mice. Data are from n = 6 or 7 mice 
per group. Statistical analysis was performed using one-tailed, t-test, *p<0.05, **p<0.01 
and ***p<0.001. Error bars represent mean ± SEM. 
 
 
Overall, our data show that TSLP targets IL-7R+ progenitors in a manner distinct 
from IL-7 to increase proliferation, up-regulate expression of the Mcl-1 pro-survival 
protein, and promote differentiation of an expanded CD34+ pro-B cell pool. This 
population is expanded and/or maintained in subsequent stages of development by TSLP 
via unidentified mechanism(s) that are independent of Bcl-2 family pro-survival protein 
expression.   
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TSLP is Expressed by Human BM Stromal Cells 
Our next step was to investigate whether the TSLP effects we observed in +T 
xenograft mice are consistent with normal in vivo human B cell development. To 
determine if BM stroma provide an in vivo source of TSLP to support human B cell 
production, we isolated RNA from the stromal cells of normal BM donors and performed 
RT-PCR. We evaluated TSLP expression, and IL-7 for comparison. Figure 3.9A shows 
that BM stromal cells express transcripts for TSLP, as well as IL-7. To verify that TSLP 
transcripts result in protein production, supernatant taken from cultured BM stromal cells 
was evaluated by enzyme-linked immunosorbant assay (ELISA). TSLP, as well as IL-7 
proteins were detected in culture supernatants (Figure 3.9B). These data demonstrate that 
human BM stromal cells produce TSLP, in addition to IL-7, and thus provide a source for 
both cytokines in vivo in the normal human BM microenvironment.    
 
 
Figure 3.9: In vivo human B cell production mirrors xenograft mice with human TSLP. (A) 
RT-PCR was used to detect TSLP, IL-7 or beta-2 microglobulin (#2M, control) transcripts 
in primary human BM stromal cells from different human donors – pediatric (BM#1 and 
BM #2) and adult (BM #3) or water as a negative control. (B) Supernatant from confluent 
BM stromal cell cultures were assessed by ELISA for TSLP and IL-7 protein production. 
Dashed lines (---) represent ELISA threshold of detection.  
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In vivo B cell Production in Patients Shows Progenitor Ratios and Mcl-1 Expression 
that Mirrors Human B cell Production in Xenograft Mice with TSLP 
In +T mice, the CD34+ pro-B compartment is expanded at the expense of IL-7R+ 
progenitors giving a dramatically different distribution of CD34+ subsets than in –T 
mice. To determine whether this altered distribution reflects normal human B cell 
development, we compared the ratio of CD19+CD34+ pro-B cells to IL-7R+ progenitors 
in BM from pediatric patients to that in xenograft mice.  Xenograft or patient BM was 
stained for flow cytometry to detect human specific B lineage and progenitor markers. 
Total living CD34+ cells were gated into CD19+CD34+ pro-B and IL-7R+ progenitors 
(Figure 3.10, left panel). In pediatric BM, the ratio of CD19+CD34+ pro-B to IL-7R+ 
progenitors was 7.2 to 1 (Figure 3.10, right panel). This was similar to that observed in 
+T xenograft mice (9.1 to 1) but significantly higher than in –T mice (1.5 to 1) (Figure 
3.10, right panel).    
 
 
Figure 3.10: Left panel: Plotted are the gated living total CD34+ cells from the BM of –T 
xenograft, +T xenograft and normal pediatric patients.  Right panel: Graphed is the ratio 
of CD34+ pro-B cells to IL-7R+ progenitors among BM-derived total CD34+ cells from –
T xenograft mice (n=3), +T xenograft mice (n=5) and from normal pediatric patient 
samples (n=10). CD34+ progenitors and early B cell subsets from the BM of normal 
pediatric patients were gated into IL-7RD– and IL-7RD+ fractions.   
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We wanted to know whether the pattern of Bcl-2 family protein expression that 
implicates IL-7RD-mediated signals in the survival of developing B cells in xenograft 
mice was also present in vivo in patient samples. Normal pediatric BM samples were 
analyzed for Bcl-2 family protein expression by flow cytometry. The pattern of up-
regulated Bcl-2 and Mcl-1 in IL-7R+ subsets of pro-B and pre-B cells that we observed 
in pediatric patient samples was similar to that observed in –T and +T xenograft mice 
(Figure 3.11, left panel). Bcl-xL showed up-regulation in some, but not all IL-7R+ 
subsets (Figure 3.11, middle panel).  Notably, in normal pediatric BM we found that Mcl-
1 was up-regulated in IL-7R+ progenitors as compared to HSC/multi-lineage progenitor 
population (CD19–CD34+IL-7R– cells) (Figure 3.11, right panel) ––a feature unique to 
B cell production in xenograft mice with TSLP. Taken together these data show that 
normal pediatric B cell development shares features unique to xenograft mice with 
human TSLP, namely a high ratio of CD34+ pro-B cells to IL-7R+ progenitors and up-
regulated Mcl-1 in IL-7R+ progenitors. 
 
 
Figure 3.11: Left panel: Graphed are MFI of Bcl-2 (n=6); middle panel: Bcl-xL (n=10) and 
right panel: Mcl-1 (n=9) in the IL-7RD–/+ fractions of normal pediatric BM. Statistical 
analysis was performed using two-tail, t-test, *p<0.05, **p<0.01 and ***p<0.001. Error 
bars represent mean ± SEM.   
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Discussion 
Here we use a novel xenograft model system that allows us to study human B cell 
development in vivo with and without TSLP and in context of IL-7 stimulation. Using 
this model we show that TSLP uniquely targets CD19–CD34+ progenitors expressing the 
IL-7RD, inducing increased proliferation and Mcl-1 expression that is not observed 
during in vivo human B cell development with IL-7 stimulation alone. Rather than 
expanding the IL-7R+ progenitor population, these activities result in a dramatically 
expanded CD34+CD19+ pro-B cell compartment suggesting that TSLP promotes the 
differentiation of newly produced cells into the B lineage. This is supported by in vitro 
experiments showing that TSLP promotes the production of CD19+Pax-5+ B lineage 
cells from CB CD34+ progenitors. In pediatric BM samples we observed a 7:1 ratio of 
CD34+ pro-B cells to IL-7R+ progenitors as well as up-regulated Mcl-1 in IL-7R+ 
progenitors. This mirrors what we observed in +T mice suggesting that the effects 
produced by TSLP occur during normal in vivo B cell development in children. 
Genetic alterations leading to activation or overexpression of the TSLP receptor 
component, CRLF2, are linked to malignant transformation and high-risk B cell 
precursor acute lymphoblastic leukemia (26, 27). This suggests a role for TSLP receptor 
activation in the proliferation and/or survival of early human B lineage cells. Our data 
show that TSLP is similar to IL-7 in that it stimulates the in vitro proliferation of normal 
B cell precursors derived from CB CD34+ cells (Figure 8). Our data in normal B cell 
precursors are consistent with previous reports (28, 29) suggesting a role for TSLP-
CRLF2 mediated signals in the proliferation of B-ALL cells. Our xenograft studies also 
suggest a role for TSLP, distinct from that of IL-7 and independent from Bcl-2 family 
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pro-survival molecules, in protecting developing CD19+ B lineage cells from death. It 
should be noted that the up-regulation of Bcl-2 family pro-survival proteins that we 
observed in IL-7R+ subsets of developing B lineage cells, with or without TSLP, could 
also be a function of TSLP that is redundant to IL-7 and therefore indistinguishable in our 
model.   
Our studies suggest TSLP has roles that are both distinct and redundant to IL-7 in 
human B cell development. It is important to note that our studies were performed using 
postnatal sources that most closely reflect B cell development in the pediatric population. 
This is important because murine studies suggest that the role of IL-7 is less critical (30) 
and TSLP may play a larger role (2, 3) at early points in life, although the latter remains 
controversial (31). Thus, it will be important to evaluate the role of TSLP during adult B 
cell development using the model that we have developed here.    
Understanding the potential contribution of TSLP to B cell production throughout 
life is important because a range of factors influence TSLP levels and potentially B cell 
production. TSLP expression is increased by environmental pollutants (32-34) and is 
elevated in inflammatory diseases including asthma, atopic dermatitis and arthritis (32-
34). Our data show that increases in circulating TSLP increases the proliferation and 
reduces the numbers of IL-7R+ progenitors. This raises the question of whether high 
levels of circulating TSLP could exhaust the lymphoid progenitor population. If so, this 
has the potential for long-term impact on the production of adaptive immune cells in 
people with chronically elevated TSLP. 
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CHAPTER FOUR 
TSLP REGULATES CELL DEATH AND CELL SURVIVAL MECHANISMS 
AND INDUCES APOPTOSIS IN CRLF2 B-ALL CELLS  
 
Abstract 
Pediatric CRLF2 B-ALL is a high-risk form of leukemia that is associated with 
poor patient survival outcomes. CRLF2 B-ALL is five (5) times more prevalent in 
Hispanic children and is associated with a higher rate of relapse. Genetic defects in the 
CRLF2 gene have led to the overexpression of the CRLF2 protein- a receptor component 
for TSLP- on the surface of B-ALL cells. The disease mechanisms of CRLF2 B-ALL are 
unclear; more importantly, the role of TSLP in the maintenance and progression of 
CRLF2 B-ALL is unknown. TSLP induces proliferation of normal human B-cell 
precursors and is produced by human bone marrow stromal cells, suggesting that it is 
present in the BM microenvironment where leukemia develops. Therefore we 
hypothesized that TSLP contributes to CRLF2 B-ALL by increasing proliferation and/or 
survival of leukemia cells via regulation of genes downstream of CRLF2 pathway 
activation. Using the novel hTSLP+/hTSLP- xenograft model, we demonstrated that 
TSLP up-regulates cell death and survival genes and biological pathways and induces 
apoptosis in CRLF2 B-ALL cells in vivo and in vitro. Further, TSLP transiently increases 
Bcl-2 pro-survival family member Mcl-1, suggesting that TSLP-induced cell death and 
survival mechanisms are mediated by Mcl-1. The studies described in this chapter 
provide evidence that TSLP plays a role in regulating the survival mechanisms of CRLF2 
B-ALL and has future implications for the treatment of this disease.  
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Abbreviations 
TSLP    Thymic Stromal Lymhopoieitin 
TSLPRE   Thymic Stromal Lymhopoieitin receptor beta (or CRLF2) 
CRLF2   Cytokine Receptor-Like Factor 2 (or TSLPRE) 
IL-7RD   Interleukin 7 Receptor alpha 
CD34    Cluster of Differentiation 34 (stem cell marker) 
CRLF2 B-ALL  CRLF2 B-cell Acute Lymphoblastic Leukemia 
JAK    Janus Kinase 
STAT    Signal Transducers and Activators of Transcription 
BaF3    Murine Pro-B cell line 
PI3K    Phosphoinositide-3-Kinase 
AKT    Protein Kinase B 
mTOR    Mammalian Target Of Rapamycin 
ERK    Extracellular signal-Regulated Kinases 
MAPK    Mitogen-Activated Protein Kinase 
hTSLP    Human TSLP 
Bcl-2    B-cell Lymphoma 2 
Bcl-xl    Bcl-2 Like protein X 
Mcl-1    Myeloid Cell Leukemia 1 
BM    Bone Marrow 
PB    Peripheral Blood 
7-AAD   7-Amino-Actinomycin D    
PDX    Patient Derived Xenograft 
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NSG    NOD/SCID Gamma (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) 
CD45    Cluster of Differentiation 45 (leukocyte marker) 
CD19    Cluster of Differentiation 19 (B-cell marker) 
CD10    Cluster of Differentiation 10 (B-cell marker) 
DGA    Discriminatory Gene Analysis 
GSEA    Gene Set Enrichment 
IPA    Ingenuity Pathway Analysis 
EIF2    Eukaryotic Initiation Factor 2 
ROS    Reactive Oxygen Species 
NADH    Nicotinamide Adenine Dinucleotide 
ER    Endoplasmic Reticulum 
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Introduction 
TSLP, initially detected in the conditioned medium of epithelial cells that are 
found in the thymic medulla is produced in the lung, bronchial tree, intestine and skin [1, 
2]. TSLP performs physiological roles in inflammation, allergic reactions, helminthic 
infections and the development of various hematopoietic cells [3-5]. High levels of TSLP 
have been linked to asthma, allergy, atopic dermatitis and autoimmune diseases [6]. 
TSLP performs its functions by signaling through the TSLP receptor, which comprises of 
the IL-7RD and TSLPRE [7]. Using microarray, Lu, et al demonstrated that different cells 
express varying levels of TSLPRE. For example, myeloid dendritic cells express high 
levels of TSLPRE; CD34+ human hematopoietic progenitor-derived mast cells express 
low levels of TSLPR; and B-cells show undetected levels of TSLPRE [8]. Surprisingly, 
the low levels of TSLPRE expressed on B-cells are sufficient for TSLP to bind and 
induce proliferation of B-cell precursors ([7]; chapter 2 and 3). However, more recently, 
several groups have shown that genetic defects in the CRFL2 (another name for 
TSLPRE) gene led to overexpression of the CRLF2 protein on the surface of leukemia 
cells [9-11]. These leukemia cells are a high-risk subset of B-cell Acute lymphoblastic 
leukemia referred to as CRLF2 B-ALL. CRLF2 B-ALL patients experience a 65% 
relapse rate and have an overall poor survival outcome [12].  
Studies conducted by Children Oncology Groups (COGs) have been directed 
towards genomic profiling and risk stratification in order to identify high-risk patients 
such as CRLF2 B-ALL patients [13, 14]. Additional studies have been conducted to 
assess CRLF2 B-ALL patient response to current treatment regimens and to determine 
therapeutic outcome, but very little is known about the mechanisms that contribute to the 
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initiation, progression and maintenance of the disease [15, 16]. Recent molecular studies 
have shown that in some cases overexpression of CRLF2 is associated with activating 
mutations in JAK2, a kinase which acts downstream of TSLP-CRLF2 interactions [17]. 
The CRLF2 gene defects and JAK2 activating mutations have been shown to cooperate in 
promoting constitutive dimerization, constitutive JAK-STAT activation and cytokine 
independent growth in the murine BaF3 cellular model system [10, 11].  
These data have led others to the conclusion that over-expression of CRLF2 and 
activating JAK mutations are the major contributors to this disease and the current dogma 
is that CRLF2 B-ALL cells do not require TSLP-induced signals for survival and 
proliferation due to constitutive activation of the JAK-STAT pathway. Therefore studies 
to evaluate the efficacy of treatments for CRLF2 B-ALL are conducted in context of 
JAK-mutations and without TSLP-induced CRLF2 signals [18]. However, all JAK 
mutations are not activating and 30% of CRLF2 B-ALL patients have no mutations in 
JAKs [17]. Furthermore, our lab and others have shown that TSLP increases the 
phosphorylation of STAT5, S6 and ERK which provided evidence of activation of the 
JAK-STAT, PI3K/AKT/mTOR and ERK pathways and more importantly in cells with 
JAK mutations [19]. Thus, the contributions of TSLP (the ligand that stimulates CRLF2 
signaling) to the maintenance/progression of CRLF2 B-ALL and the cellular and 
molecular mediators involved remain to be elucidated.  
Here we use a novel hTSLP+/hTSLP- human-mouse xenograft in vivo system, in 
vitro studies and gene arrays to show that TSLP regulates cell death and survival 
mechanisms and induces apoptosis in CRLF2 B-ALL cells, in spite of the up-regulation 
of Bcl-2 family member Mcl-1. 
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Materials and Methods 
Mice 
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
(Jackson Laboratory). Mice were housed under pathogen-free conditions in the Loma 
Linda University Animal Care Facility and studies were conducted in accordance with 
Loma Linda University Institutional Animal Care and Use Committee (IACUC) 
approved protocols. Leukemia cell lines and primary cells (CRLF2 B-ALL and non-
CRLF2 B-ALL primary cells) were expanded in NSG mice for 9-11 weeks. Animals 
were euthanized at end point by CO2 asphyxiation. Animal tissues including bone 
marrow (BM), spleen and peripheral blood (PB) were harvested and processed. BM cells 
were collected by removing long bones (femora, humeri) from mice and flushing the 
bones with a PBS solution using a syringe.  
 
In vivo Apoptosis Assay 
hTSLP+/hTSLP- mice were produced by injecting NSG mice weekly with 5X106 
HS27 stromal cells that were transduced with a lentiviral vector that expresses human 
TSLP (hTSLP+) or an empty vector (hTSLP-). Mice were then transplanted with 5-
10X106 human CRLF2 B-ALL cell lines or primary cells. Prior to euthanasia, TSLP 
levels in animal sera were measured weekly by ELISA to monitor the levels of human 
TSLP in hTSLP+ mice and hTSLP– mice. CRLF2 B-ALL cells expanded in hTSLP+ or 
hTSLP- mice were harvested from tissues (BM, spleen and PB) and stained for flow 
cytometry analysis with the following markers: mouse CD45 to identify mouse 
leukocytes; human CD19 to identify human B-ALL cells; TSLPR (CRLF2) to identify 
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CRLF2+ B-ALL cells as a measure of bone marrow disease; and Annexin V and/or 7-
AAD to detect cells that are in early or late stages of apoptosis.  
 
Whole-genome Microarray 
Primary CRLF2 B-ALL cells were harvested from the BM of hTSLP+ and 
hTSLP- mice and hCD19+ B-ALL cells were isolated by magnetic separation using the 
MACS cell separation kit (Miltenyi Biotec). After separation, cells were rapidly frozen 
and shipped to Miltenyi Biotec for sample preparation, whole genome microarray, and 
discriminatory gene analysis (Miltenyi Genomic Services, Germany). 
 
In vitro Apoptosis Assay 
CRLF2 B-ALL cell lines or primary cells were maintained in RPMI 1640 medium 
supplemented with penicillin/streptomycin, L-glutamine, 50 uM 2-ME and 20% fetal 
bovine serum (FBS). Cells were cultured with the above media in the presence or absence 
of TSLP for 3, 6 or 9 days, then harvested and stained with Annexin V and 7-AAD to 
identify cells in early stages (Annexin V+, 7-AAD–) or late stages (Annexin V+, 7-
AAD+) of apoptosis for flow cytometry analysis. This experiment was repeated with IL-
7. Cell cultures included neutralizing antibodies to TSLP or IL-7 and nonspecific isotype 
matched control antibodies.  
 
In vitro Pro-survival Protein Assay 
CRLF2 B-ALL cells were cultured in cell culture media with or without TSLP 
along with the appropriate controls (described above) for 3, 6 or 9 days. Cells were 
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harvested and assessed for the expression of Bcl-2 family members (anti-apoptotic 
proteins: Bcl-2, Bcl-xl and Mcl-1) using a caltag fixation and permeabilization 
intracellular flow cytometry protocol (Life Technologies). 
 
Results 
TSLP Induces Apoptosis in CRLF2 B-ALL Cells In vivo 
The development of the novel hTSLP+/hTSLP- xenograft model described in 
chapter 2 provided an in vivo tool that can be used to study the role of TSLP in normal 
human B-cells (see chapter 3) and most importantly the role of TSLP in CRLF2 B-ALL. 
Using the hTSLP+/hTSLP- model, data described in chapters 2 and 3 showed that TSLP 
induces proliferation and survival of normal B-cells and induces activation of the mTOR 
pathway and its related genes in primary CRLF2 B-ALL cells. These data provided 
evidence that 1) the hTSLP+/hTSLP- model provides the human TSLP-CRLF2 
interactions that are required to activate normal human B-cells and human CRLF2 B-
ALL cells in vivo and 2) hTSLP induces cell proliferation and cell survival signals in 
normal B-cells. The results obtained from the studies that evaluated the effects of TSLP 
on normal B-cells supports our hypothesis that TSLP induces proliferation and survival in 
these cells, however, the effects of TSLP on human CRLF2 B-ALL cells remain to be 
elucidated. Therefore, using the novel hTSLP+/hTSLP- xenograft model, we evaluated 
the effects of TSLP on CRLF2 B-ALL cells by testing the overarching hypothesis that 
TSLP contributes to CRLF2 B-ALL by increasing proliferation and/or survival of 
leukemia cells via regulation of genes downstream of CRLF2 pathway activation.  
 To test this hypothesis, first we evaluated the effects of TSLP on CRLF2 B-ALL 
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cells in vivo by creating patient-derived xenografts (PDXs), administering varying levels 
of TSLP and assessing leukemia cell viability. PDXs were developed by transplanting 
NSG mice with primary CRLF2 B-ALL cells via tail vein injections and allowing the 
cells to expand in vivo for 9-11 weeks. Prior to or on the day of leukemia cell 
transplantation, NSG mice were injected with either low levels of TSLP (<10 pg/ml) or 
higher levels of TSLP (~20 pg/ml) and leukemic cell BM chimerism was determined 
using mouse and human cell markers. To accomplish this, BM cells were harvested from 
mice at euthanasia, cells were co-stained with mouse CD45, human CD19 and human 
CRLF2 to determine engraftment of human leukemia cells; and Annexin V to identify 
apoptotic cells.  
 When low levels of TSLP were administered, our data showed that ~88% of cells in 
the BM of +T mice were CRLF2 B-ALL cells while 83% of cells in the BM of –T mice 
were CRLF2 B-ALL cells (Figure 4.1, top panel). Engrafted cells were mCD45–
hCD19+hCRLF2+. The percent of cells engrafted is a measure of BM disease, therefore 
based on this definition, the data suggests that there is no difference in BM disease in +T 
mouse compared to –T mouse.  
To determine the effect of TSLP on the viability of engrafted cells, BM cells were 
also stained with Annexin V and 7-AAD. Cells were first gated using mCD45, hCD19 
and hCRLF2 to determine the percent of hCD19+ cells (Figure 4.1, top panel) and the 
percent CRLF2 B-ALL cells (Figure 4.1, middle panel). The engrafted cells were gated to 
show Annexin V+ cells. The dot plot showed that the percent of living hCD19+ cells in 
the BM of +T mouse was half as much as the percent of hCD19+ cells in the BM of –T 
mouse (Figure 4.1, bottom panel). Our data showed no observable differences in BM 
90 
engraftment in +T and -T mice, however, there is a higher percent of apoptotic leukemic 
cells in the BM of the +T mouse compared to -T mouse.  
 
 
Figure 4.1: Primary CRLF2 B-ALL cells were injected into –T and +T mice and animals 
were euthanized 9 weeks post transplant, BM was harvested and cells were co-stained with 
mCD45, hCD19, hCRLF2 and Annexin V. hCD19+ cells were sub-gated to determine the 
percent of CRLF2+ and Annexin V+ cells.  
 
 
When higher levels of TSLP was administered, our data showed that for primary 
CRLF2 B-ALL#1, 2.35 % of cells in the BM of +T mice were CRLF2 B-ALL cells 
compared 28.1 % of cells in the BM of –T mice- n=2 (Figure 4.2, top panel). For primary 
CRLF2 B-ALL#2, 0.2% of cells in the BM of +T mice were CRLF2 B-ALL cells, 
compared to 95% of cells in the BM of –T mice- n=2-10(Figure 4.2, bottom panel). 
Therefore at low levels of TSLP there was no observable difference in BM engraftment, 
while at higher levels of TSLP, there was a dramatic decrease in the percent of CRLF2 B-
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ALL cells engrafted in the BM of +T mice. Data obtained from secondary and tertiary 
CRLF2 B-ALL PDX showed similar results, irrespective of the source of the cells for the 
2o and 3o transplants, i.e. irrespective of whether BM or Spleen cells were used. The data 
suggests that at higher doses (~20 pg/ml – reported physiological levels), TSLP exerts an 
effect on CRLF2 B-ALL BM disease- that is, TSLP specifically reduces the tumor 
burden in mice. 
 
 
Figure 4.2: Primary CRLF2 B-ALL cells from two different patients (B-ALL#1 and B-
ALL#2) were injected into –T and +T mice and animals were euthanized 9-11 weeks post 
transplant, BM was harvested and cells were co-stained with mCD45, hCD19 and hCRLF2. 
Gated hCD19+ cells is a measure of BM disease.  
 
 
 
Results from staining with apoptotic markers and gating cells as described above 
in figure 4.1 showed that the CRLF2 B-ALL cells engrafted in +T mice and –T mice 
when during higher levels of TSLP, were Annexin V–. Virtually all cells engrafted in the 
BM of +T as well as –T mice were viable living cells. 
 In summary, our data showed that when low levels of TSLP is present in +T mice, 
there’s  a  higher  percentage  of  CRLF2  B-ALL cells in the BM, but most of these cells 
undergo apoptosis. However, when higher levels of TSLP are present in the +T mice, 
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there is low to no engraftment of CRLF2 B-ALL cells and these engrafted cells are 
viable. Taken together, these data suggest that increasing the levels of TSLP produces a 
differential effect on CRLF2 B-ALL cells in vivo. Further, this differential effect of TSLP 
is demonstrated by its induction of apoptosis in leukemia cells at lower levels and the 
absence of leukemia cells at higher levels. Moreover, these results were 
observed/maintained over subsequent transplants and were unique to the +T condition 
irrespective of the source of cells. 
 
TSLP Activates Cell Death and Survival Pathways and Cellular Functions in CRLF2  
B-ALL Cells In vivo 
 In order to gain a better understanding of how TSLP regulates the cellular 
functions we observed in CRLF2 B-ALL cells in vivo, we performed whole genome 
microarray studies to identify genes that are up-regulated by TSLP, the biological 
pathways that are implicated by these genes, and the molecular and cellular functions that 
ensue as a result of the up-regulation of these genes and pathways. To accomplish this, 
primary CRLF2 B-ALL cells were expanded in +T and -T mice for 9 weeks, BM was 
harvested, CD19+ leukemia cells were isolated by magnetic separation and the cells were 
shipped to Miltenyi Biotec (Miltenyi Genomic Services) for whole genome microarray 
and discriminatory gene analysis (DGA). GSEA and IPA were performed using whole 
genome microarray data files. Results from GSEA analysis showed that TSLP induced 
activation of the mTOR pathway and its related genes in primary CRLF2 B-ALL cells 
that were expanded in +T compared to –T mice (chapter 2 and Table 6). Studies have 
shown that the mTOR pathway functions to regulate cell growth and survival [20]. IPA 
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results provided additional evidence that the mTOR pathway was up-regulated by TSLP 
in these cells. In addition to the mTOR pathway, the IPA results also showed that a list of 
other canonical pathways were significantly up-regulated (compared to mTOR) by TSLP 
in CRLF2 B-ALL cells (Figure 4.3).  
 
 
Figure 4.3: Ingenuity Pathway Analysis (IPA) was performed based on gene reporters that 
were significantly up-regulated (2.0 fold,  p≤0.05).  Graphed  are   the  canonical  pathways  
significantly enriched in samples taken from +T as compared to –T mice. 
 
 
 The data showed that in addition to the mTOR pathway, mitochondrial dysfunction 
(most significantly up-regulated) followed by EIF2 signaling and other cell metabolism 
pathways were also up-regulated by TSLP (Figure 4.3). Studies have shown that 
mitochondrial dysfunction is linked to the generation of reactive oxygen species (ROS) in 
cells; it affects processes such as lipid metabolism; and is implicated in the intrinsic 
(mitochondrial) apoptosis pathway [21-23]. EIF2 signaling has been shown to regulate 
protein translation in response to cellular stress that is induced by viral infection, heme 
deprivation, oxidative stress, ER stress, nutrient deprivation, heat shock, proteasome 
inhibition and UV irradiation [24]. Other studies have also shown that EIF2 can activate 
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both pro-apoptotic and pro-survival cellular pathways [25, 26]. Alternatively, mTOR 
signaling has been shown to induce cellular growth and proliferation [27]. Careful 
investigation of the top 10 pathways listed showed that  mitochondrial dysfunction, EIF2 
signaling, MAPK signaling in influenza are involved in cell death/cell stress mechanisms; 
while eIF4 and p70S6K signaling, glycolysis, gluconeogenesis, TGFE , PRPP 
Biosynthesis, NADH repair and HMGB1 signaling are involved in cell survival 
mechanisms.  
 Additional IPA analyses revealed that the top associated network function that was 
up-regulated in the +T CRLF2 B-ALL sample but not in the –T sample was the network 
responsible for cellular assembly, cellular organization, cellular death and survival and 
cellular morphology. Most importantly, the top cellular and molecular function of the cell 
that was up-regulated by TSLP is cell death and survival, with a total of 34 genes 
involved in these processes (Table 1). Cell death and survival was followed by other 
cellular functions including free radical scavenging, lipid metabolism, molecular 
transport and small molecule biochemistry. In summary, the biological pathways up-
regulated by TSLP reflect the involvement of cell death, cell stress and cell survival 
mechanisms. This data is further supported by the results that showed that the top cellular 
and molecular function of the cell that was regulated by TSLP was cell death and 
survival. Taken together, these data suggest that both cell death and cell survival 
functions as well as their downstream pathways are involved in TSLP-CRLF2 signaling 
in CRLF2 B-ALL cells that were expanded in the +T mouse. 
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Table 1: List of cellular and molecular functions that are up-regulated by TSLP in primary 
CRLF2 B-ALL cells expanded in +T mice compared to –T mice. The number of molecules 
refers to the number of genes that are up-regulated by TSLP and contribute to the respective 
cellular/molecular functions listed to the left.   
 
 
 
 
TSLP Induces Apoptosis in CRLF2 B-ALL Cells In vitro 
The molecular data obtained from the IPA of CRLF2 B-ALL +T and –T PDXs 
suggested that TSLP may play a role in regulating cell death and cell survival 
mechanisms and further substantiated the apoptotic effects of TSLP on CRLF2 B-ALL 
cells that was observed in vivo. Therefore to further elucidate the mechanisms by which 
TSLP regulates cell death and survival, we evaluated the effects of TSLP on CRLF2 B-
ALL cells in vitro. To accomplish this, we cultured human CRLF2 B-ALL cell lines with 
or without TSLP for 3, 6 or 9 days and assessed cell death by staining cells with apoptotic 
markers- Annexin V and 7-AAD. Cells were split every 3 days and fresh media 
containing cytokines was added. Cells that undergo early apoptosis were detected using 
Annexin V while cells that undergo late apoptosis were detected using 7-AAD. Total 
percent of apoptotic cells was represented as cells that were Annexin V+7-AAD+, while 
the percent of living cells was represented as cells that were Annexin V-7-AAD-. The 
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total number of living cells in culture under each condition and at each time point was 
determined by trypan blue cell counts.  
Our results showed that there was no significant difference in the percent of 
apoptotic cells between cells that were treated with TSLP compared to untreated cells at 
day 3 (Figure 4.4, top-left panel). Similarly, there was no significant difference in the 
number of living cells in culture between cells that were treated with TSLP and those that 
were untreated (Figure 4.4, bottom-left panel). However, at day 6 there was an increase in 
the percent of apoptotic cells in the cultures that were treated with TSLP compared to 
untreated controls (Figure 4.4, top-middle panel). In support of the observed increase in 
the percent of apoptotic cells, we observed a decrease in the total number of living cells 
present in the cultures that were treated with TSLP compared to the untreated control 
(Figure 4.4, bottom-middle panel). Similarly, at day 9 we observed a pronounced increase 
in the percent of apoptotic cells in the cultures that were treated with TSLP compared to 
controls (Figure 4.4 top-right panel) and substantial decrease in the total number of living 
cells in these cultures (Figure 4.4 bottom-right panel). Further, the percent apoptosis in 
cells treated with TSLP at day 3 was very low (~20%) compared to day 6 (~50%) and 
day 9 (~80%) (Figure 4.4). Overall, the data showed that TSLP induces apoptosis in 
CRLF2 B-ALL cells in vitro which is increased at later time points, even though the 
concentrations of TSLP that was administered at each time point remained the same. 
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Figure 4.4 CRLF2 B-ALL cells were cultured in culture media with or without TSLP, IL-
7 or both for 3, 6 and 9 days. Cells were split every 3 days for the duration of experiment. 
Cells were harvested and stained with Annexin V and 7-AAD and assessed by flow 
cytometry. Graphs show the percent of apoptotic cells that are in the early stage (Annexin 
V+-yellow) or late stage (7-AAD+- red) of apoptosis. Living cells are Annexin V-7-AAD- 
blue). 
 
 Since a component of the TSLP receptor (IL-7RD) is shared by the cytokine IL-7, 
which is also produced by human BM stroma and is known to promote survival and 
proliferation of human B-cells [28]; we also evaluated apoptosis in cells grown with or 
without IL-7. Our results showed that at day 3, there was no difference in the percent of 
apoptotic cells in cultures treated with IL-7 compared to untreated cells. Similarly, there 
was no difference in the total number of living cells in the IL-7 cultures compared to the 
untreated cells. At days 6 and 9, we also observed no difference in the percent of 
apoptotic cells between the IL-7 cultures and controls, however, there was an increase in 
the total number of living cells in the IL-7 cultures compared to the untreated controls on 
days 6 and 9 (Figure 4.4). These data suggest that IL-7 increases cell survival by 
protecting cells from apoptosis and may also be inducing cells to proliferate.  
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 In summary, our in vitro culture studies suggest that TSLP reduces cell survival 
by inducing apoptosis in cells while IL-7 increases cell survival by protecting cells from 
apoptosis.. Additionally, the in vitro data provides further evidence to support the in vivo 
data by demonstrating that TSLP induces apoptosis in CRLF2 B-ALL cells and 
strengthens the molecular data which emphasized that TSLP induces cell death and cell 
survival pathways. 
 
TSLP Up-regulates Mcl-1 Expression as a Cell Survival Mechanism Prior to Inducing 
Apoptosis in CRLF2 B-ALL Cells In vitro 
 The IPA data showed that cell death and survival are the most significant cellular 
and molecular functions of the cell that are up-regulated by TSLP in primary CRLF2 B-
ALL cells (Table 1). In addition, IPA also showed that while cell survival pathways such 
as mTOR and cell metabolism are up-regulated, cell death (mitochondrial dysfunction) 
and cellular stress pathways (EIF2 signaling) are also up-regulated by TSLP in these cells 
(Figure 4.3). Moreover, although pathways that produce opposing cellular functions (cell 
death versus survival) are activated by TSLP, the most significantly up-regulated 
pathways are the cell death and cellular stress pathways. This idea is strikingly 
demonstrated in the functional evidence provided by the in vitro data. The in vitro data 
showed that at day 3, cells are maintained in culture, but they ultimately undergo 
apoptosis at later time points. This data suggests that TSLP-induced signaling in CRLF2 
B-ALL cells may involve regulation of the pro-survival versus pro-apoptotic switch. 
Therefore we wanted to elucidate the mechanisms involved in the TSLP-induced survival 
versus apoptosis.  
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 Apoptosis (programmed cell death) is a mechanism used by cells to regulate cell 
numbers, to remove pathogens or to remove cellular debri and is often activated as a 
result of DNA damage, loss of cell-survival factors or due to cellular stress. This process 
may be intrinsic (initiated within the mitochondrion of the cell) or extrinsic (death 
receptor mediated). Since the IPA data provided evidence that mitochondrial dysfunction 
is up-regulated by TSLP in CRLF2 B-ALL cells, we focused our attention on 
mitochondrial mechanisms that regulate the pro-apoptotic versus anti-apoptotic signals 
within a cell. The intrinsic cell death pathway is regulated by the Bcl-2 family of proteins 
[29]. These proteins function to regulate the permeability of the mitochondrial membrane 
and to determine whether pro-apoptotic or anti-apoptotic signals will prevail in the cell 
[23]. Under cellular stress conditions, Bcl-2 pro-apoptotic family members are activated 
and direct the release of caspase activators in the mitochondria. Conversely, the Bcl-2 
anti-apoptotic family members such as Bcl2, Bcl-xl and Mcl-1 are up-regulated to 
prevent the cell from undergoing apoptosis and function to increase cell survival. In order 
to understand the mechanisms involved in the survival of CRLF2 B-ALL cells at day 3, 
we evaluated the expression of the anti-apoptotic Bcl2 family members in human CRLF2 
B-ALL cell lines in vitro.  
To accomplish this, first we cultured primary CRLF2 B-ALL cells that were 
harvested from the BM of PDXs with or without TSLP for 3 days in vitro. At day 3, cells 
were harvested from culture, hCD19+ B-ALL cells were isolated by magnetic separation 
and cells were sent for whole genome microarray analysis. The DGA results showed that 
there was no change in the gene expression profile of Bcl-2 family members (pro-
apoptotic and pro-survival) except for Mcl-1. The data showed that Mcl-1 was up-
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regulated 1.6 fold in CRLF2 B-ALL cells that were treated with TSLP compared to 
untreated cells in vitro.  
 Next, we cultured CRLF2 B-ALL cell lines with or without TSLP in vitro for 3 
days and assessed the expression of Bcl-2 pro-survival proteins. At day 3, cells were 
harvested from culture and the expression of Bcl-2 family pro-survival members Bcl-2, 
Bcl-xl and Mcl-1 was measured using intracellular flow cytometry. Our data showed no 
increases in Bcl-2 expression in cells stimulated with TSLP compared to untreated cells 
(Figure 4.5 left panel). However there was a minimal increase in the expression of Bcl-xl 
in TSLP treated cells  (Figure 4.5 middle panel) and a substantial increase in the 
expression of Mcl-1 in TSLP treated cells compared to controls (Figure 4.5, right panel). 
Taken together the data shows that at day 3, TSLP has no effect on Bcl-2, but has an 
effect on Bcl-xl and Mcl-1. The increases observed for Mcl-1 suggests that at day 3, 
TSLP treated cells may be surviving primarily due to Mcl-1 expression.  It is possible 
that by days 6 and 9, the cellular stress induced by TSLP overcomes the Mcl-1-induced 
pro-survival mechanisms and induces apoptosis in CRLF2 B-ALL cells in vitro.  
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Figure 4.5: CRLF2 B-ALL cells were cultured in culture media with or without TSLP, IL-
7 or both for 3. Cells were split every 3 days for the duration of experiment. Cells were 
harvested and stained with antibodies to Bcl-2, Bcl-xl, and Mcl-1 and assessed by 
intracellular flow cytometry. Histograms of all conditions are overlaid (No cytokine – red; 
TSLP- green; IL-7- blue; Both cytokines- orange). 
 
 
 
 We also evaluated the effects of IL-7 on the expression of Bcl-2 pro-survival 
family members in CRLF2 B-ALL cells in vitro. The results showed that at day 3, IL-7 
had no effect on Bcl-2 or Bcl-xl protein expression, however IL-7 increased Mcl-1 
expression in CRLF2 B-ALL cells. Interestingly enough, the increase in Mcl-1 
expression due to IL-7 stimulation was greater than that observed in cells that were 
treated with TSLP. This data suggests that both cytokines have the ability to increase 
Mcl-1 expression in this cellular system.  
In summary our data provides evidence that TSLP maintains cell survival at 72 
hrs by up-regulating Mcl-1, while TSLP induces apoptosis at later time points, possibly 
due to the down-regulation of Mcl-1 over time in vitro. Future experiments that 
investigate the expression of Mcl-1 and other Bcl-2 pro-survival family members at later 
Mcl-1Bcl-2 Bcl-xl
Both 
TSLP 
IL-7 
No Cytokine 
%
 o
f M
ax
102 
time points (days 6 and 9) are required to confirm this hypothesis. In addition, the up-
regulation of Mcl-1 protein expression by TSLP and IL-7 suggests that 1) Mcl-1 plays a 
crucial role in the cytokine-mediated survival of CRLF2 B-ALL cells and 2) provides 
evidence that Mcl-1 is a potential molecular target that can be targeted by therapeutic 
candidates in order to improve treatment outcomes for CRLF2 B-ALL.  
 
Discussion 
 In normal B-cells, which express low levels of CRLF2, TSLP binds its receptor 
and activates the JAK/STAT pathway to induce proliferation in these cells in vitro [7]. 
Using the hTSLP+/hTSLP- xenograft model, our studies provide additional data showing 
that TSLP also induces survival in B-linage cells in vivo (chapter 3). In context of these 
studies, using the hTSLP+/hTSLP- xenograft model, we evaluated the effects of TSLP on 
CRLF2 B-ALL cells, which express higher levels of CRLF2. In this chapter, we 
demonstrate that at the genetic level, TSLP induces genes involved in cell death and 
survival pathways as well as genes involved in cell death and survival cellular and 
molecular functions in CRLF2 B-ALL cells. At the cellular level, our results show that 
TSLP induces apoptosis in CRLF2 B-ALL cells in vivo as well as in vitro. The findings 
from this chapter which show that TSLP induces apoptosis in CRLF2 B-ALL cells 
(CRLF2 high) is opposite to the findings from the previous chapter which show that 
TSLP induces proliferation and survival in normal B-cells (CRLF2 low). These data 
suggest that TSLP exerts different functional effects in normal B-cells, which express 
low levels of CRLF2 and B-cell leukemia cells, which express high levels of CRLF2.  
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A plausible explanation for the difference in functional effects that was observed 
in normal B-cells stimulated with TSLP compared to CRLF2 B-ALL cells stimulated 
with TSLP is the difference in activation of key mediators in TSLP-CRLF2 signaling 
pathways. Studies of TSLP-induced pathways show that in normal B-cells, TSLP induces 
weak activation of STAT5 (low level of pSTAT5), but is still able to induce proliferation 
in B-cells [7]. Initial studies that were conducted to understand the signaling mechanisms 
involved in CRLF2 B-ALL demonstrated that in the absence of TSLP, basal levels of 
pSTAT5 were observed [9]. Further investigation of the pathways activated downstream 
of CRLF2 in our studies show that TSLP increases the phosphorylation of STAT5 and 
ribosomal protein S6 in CRLF2 B-ALL cells in vitro (chapter 1). Data from other studies 
that evaluated the effects of TSLP on signaling pathways in CRLF2 B-ALL cells also 
observed increases in the phosphorylation of STAT5, S6, AKT and ERK, thus supporting 
our in vitro data [30]. Additionally, Tasian et al surmised that the observed increases in 
phosphorylation of proteins that are key regulators of the JAK/STAT and mTOR 
pathways suggests that there is increased activation of these pathways. Therefore they 
hypothesized that aberrant signaling occurs in CRLF2 B-ALL cells.  However, studies 
conducted by Tasian et al did not address the long-term functions of TSLP (and this 
aberrant signaling) on the maintenance and progression of CRLF2 B-ALL. Our studies 
provide for the first time, evidence that shows that TSLP indeed induces aberrant 
signaling in CRLF2 B-ALL cells (signaling that is different from normal B-cells) and that 
this aberrant signaling results in the induction of apoptosis in CRLF2 B-ALL cells.  
The mechanisms involved in the TSLP-induced apoptosis of cells are unclear. 
Results from our IPA show that TSLP induces mitochondrial dysfunction and EIF2 
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signaling in CRLF2 B-ALL cells, suggesting that the mechanisms may involve 
mitochondrial-mediated cell death and the cellular stress pathway. A credible argument 
that supports that TSLP may be inducing apoptosis via mitochondrion-mediated 
mechanisms, is the fact that we see an involvement of the Bcl-2 family members. The 
Bcl-2 family plays a pivotal role in regulating mitochondrial cell death and cell survival 
[23, 29] and our evaluation of the Bcl-2 anti-apoptotic proteins showed that Mcl-1 may 
be involved in maintaining the survival of CRLF2 B-ALL cells transiently prior to the 
induction of apoptosis. Another argument is that TSLP may employ EIF2 signaling 
pathways to induce cellular stress which overcomes cell survival mediated mechanisms 
such as the up-regulation of Mcl-1, and contribute to apoptosis in CRLF2 B-ALL cells. 
Studies have shown that environmental and/or endogenous stress signals can trigger the 
phosphorylation of eIF2D- a major component of the EIF2 pathway [24]. Prolonged 
activation of this pathway has been shown to induce apoptosis in cells [24]. Further, 
studies have confirmed that phosphorylation of eIF2D is coupled to the mitochondrial-
mediated cell death machinery, which in turn down-regulates Mcl-1 expression, induces 
activation of Bax and bak resulting in apoptosis. To further support this argument, other 
studies have shown that Mcl-1 enhances the survival of hematopoietic cells and other cell 
types that are placed under apoptosis-inducing conditions and this enhancement is often 
short-term compared to that induced by Bcl2 [31]. Therefore studies that 1) evaluate the 
expression of Mcl-1 at later time points when apoptosis is observed in CRLF2 B-ALL 
cells and 2) evaluate the effects of TSLP on the expression of pro-apoptotic Bcl-2 family 
members and caspases which are part of the cell death machinery for the intrinsic 
pathway will provide evidence that validate the argument that TSLP induces apoptosis in 
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CRLF2 B-ALL cells by activating the EIF2 cellular stress and the mitochondrial 
pathways.  
Overall,  TSLP’s  ability  to  induce  apoptosis  in  CRLF2 B-ALL cells provides a 
rationale for conducting future studies that can evaluate its therapeutic potential in the 
treatment of CRLF2 B-ALL. Further, the increased expression of Mcl-1 upon TSLP and 
IL-7 stimulation, provide evidence that Mcl-1 is involved in cytokine-mediated 
mechanisms and therefore provides a rationale for also evaluating the efficacy of mcl-1 
inhibitors on CRLF2 B-ALL cells. If these studies are fruitful, then TSLP in combination 
with Mcl-1 inhibitors may prove to be beneficial for the treatment of CRLF2 B-ALL.  
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CHAPTER FIVE 
IDENTIFICATION OF SMALL MOLECULE DRUGS THAT SHOW EFFICACY 
AGAINST CRLF2 B-ALL AND OTHER HIGH-RISK B-ALL   
 
Abstract 
Patients diagnosed with high-risk B-ALL including CRLF2 B-ALL experience 
high rates of relapse and poor patient survival outcomes. Current chemotherapy regimens 
have been successful at achieving >95% remission rates, but they have been unsuccessful 
at treating patients that relapse and subsequently experience a poor prognosis. The 
success of Imatinib- a small molecule kinase inhibitor that targets the aberrant tyrosine 
kinase that is encoded by the BCR-ABL oncogene- which was used in combination with 
other chemotherapy agents to treat Ph+ hematological malignancies provided a paradigm 
for the use of targeted therapy in high-risk cancers. Therefore, using a similar approach, 
we identified two categories of small molecule drugs that are known to inhibit genetic 
lesions and cellular processes involved in high-risk B-ALL cells and reduce cellular 
survival. Here we show that the Mcl-1 inhibitor MIM1 showed efficacy by reducing the 
survival of CRLF2 B-ALL cells in vitro. We also show that the NM drug series showed 
efficacy by reducing the survival of chemo-resistant high-risk B-ALL cells in vitro and 
increasing the survival of NSG mice in vivo. The drug candidates that were identified and 
evaluated in these studies can be used for further preclinical testing on high-risk B-ALL 
subsets in order to determine their therapeutic value. They offer the potential to be used 
in combination with standard chemotherapy that is currently used to treat high-risk B-
ALL.  
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Abbreviations 
ALL   Acute Lymphoblastic Leukemia 
B-ALL  B-cell Acute Lymphoblastic Leukemia 
MRD   Minimal Residual Disease 
BCR-ABL  Breakpoint Cluster Region joined to ABL1 gene 
CRLF2  Cytokine Receptor Like Factor 2 
MIM1   Mcl-1 Inhibitor Molecule 1 
Mcl-1   Myeloid Cell Leukemia 1 
7-AAD  7-Amino-Actinomycin D 
TSLP   Thymic Stromal Lymphopoietin 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NSG   NOD/SCID Gamma (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) 
DMSO   Dimethyl Sulfoxide  
TKI   Tyrosine Kinase Inhibitor 
ABT-737  Bcl-2, Bcl-xl and Bcl-w inhibitor 
IL-7   Interleukin 7 
IC50           Half maximal Inhibitory Concentration 
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Introduction 
ALL is heterogeneous, thus treatment is administered based on phenotype, 
genotype and risk factors [1]. Current therapies for high-risk ALL patients include 
intense combination chemotherapy and/or allogenic bone marrow transplant [2]. 
Treatment for children with ALL is typically divided into two phases: 1) remission-
induction phase: this occurs at the time of diagnosis and the goal is to eradicate 99% of 
initial leukemic cells and restore normal hematopoiesis; 2) post-induction therapy 
phase: this occurs after complete remission and involves either intensification therapy 
and/or continuation therapy to remove the residual disease [1, 3]. Remission-induction 
chemotherapy consists of a combination of 3 drugs: vincristine, glucocorticoid 
(prednisone or dexamethasone), and L-asparaginase or anthracycline in conjunction with 
intrathecal therapy. In most cases, the result of such a combination is a complete 
remission rate of greater than 95-98% in patients. Children with higher risk are often 
treated with a combination of four or more drugs during induction therapy [1]. A 
commonly used treatment regimen for high-risk childhood ALL include high-dose 
methotrexate with mercaptopurine, high-dose asparaginase given for an extended period, 
and re-induction treatment [4]. Tyrosine kinase inhibitors such as Imatinib are currently 
used concurrently with chemotherapy to treat high-risk BCR-ABL+ ALL patients and 
JAK recommended for clinical trials [5]. 
Despite the improvements, intense combination chemotherapy currently used to 
treat high-risk B-ALL patients fails in ~25% of patients [6]. Patients experience relapse 
and a poor prognosis with relapse being the leading cause of cancer-related death in 
children [6, 7]. The current chemotherapy provides little scope for significant 
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intensification because there are many short-term and long-term side effects in patients 
due to toxicity and it has not been successful in reducing minimal residual disease (MRD) 
and the incidence of relapse [5]. Most high-risk cases occur due to the presence of genetic 
lesions in patient genotype that are unique to subsets of patients and are not targeted by 
general chemotherapy. As a result, these genetic lesions contribute to MRD, relapse and 
poor patient survival subsequent to remission. Therefore our goal was to identify 
potential therapeutic candidates that can target molecular lesions that were identified in 
chapter 4 and in previous studies and determine the efficacy of these drugs in decreasing 
the survival of high-risk leukemia cells.  
Here we evaluated the efficacy of the Mcl-1 inhibitor MIM1 and two new classes 
of Novomedix small molecule drugs and demonstrated that these drugs have the ability to 
reduce the survival CRLF2 B-ALL cells and high-risk B-ALL cells respectively.  
 
Materials and Methods 
In vitro Mcl-1 Inhibitor MTT Assay 
CRLF2 B-ALL cell line was maintained in RPMI 1640 phenol red free medium 
supplemented with penicillin/streptomycin, L-glutamine, 50 uM 2-ME and 20% fetal 
bovine serum (FBS). Cells were then cultured in the above media with varying 
concentrations of Mcl-1 inhibitor MIM1 at 37oC and 5.0 % CO2 using a 96 well plate (in 
triplicate). At 72 hrs, cells were removed and the MTT assay was performed using the 
Vybrant MTT cell proliferation assay kit (Life Technologies). The plate containing the 
cells was read using a microplate absorbance reader. Absorbance is read at 570nm. 
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In vitro NM Drug Apoptosis Assay 
Nalm6 cells were maintained in RPMI 1640 medium supplemented with 
penicillin/streptomycin, L-glutamine, 50 uM 2-ME and 10% fetal bovine serum (FBS). 
Cells were then cultured with the above media and NM drugs (735, 785 or 869) or 
DMSO control for 48 hrs. Cells were harvested at 48 hrs and stained with Annexin V and 
7-AAD to identify cells in early apoptotic (Annexin V+, 7-AAD–) or late apoptotic 
(Annexin V+, 7-AAD+) stages using flow cytometry. The IC50 of the drug candidates 
were obtained from the drug company and drugs were administered at their respective 
IC50 
 
In vivo NM Drug Efficacy Assay 
NSG mice were transplanted with Nalm6 cells. Eight (8) days after 
transplantation, drugs were administered to mice daily according to the following drug 
conditions: 922, 1123, 911, vincristine, vehicle and untreated. Mice were evaluated daily 
by observation and time of death was recorded in order to plot a survival curve. 
 
Results 
Mcl-1 Inhibitor MIM1 Reduces Cell Viability in CRLF2 B-ALL Cells In vitro 
TSLP-induced up-regulation of the Mcl-1 gene and protein in CRLF2 B-ALL 
cells described in chapter 4 and TSLP-induced up-regulation of Mcl-1 protein in IL-7R+ 
progenitors in normal B-cells described in chapter 3 supports the idea that Mcl-1 may 
impact B-cells by contributing to cell survival. Further, the increases in Mcl-1 protein 
expression observed in CRLF2 B-ALL cells upon TSLP stimulation and the increases in 
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Mcl-1 expression as well as cell survival observed at later time points (days 6 and 9) 
upon IL-7 stimulation, provide further evidence that Mcl-1 plays an important role in the 
survival of B-ALL cells (chapter 4). Together, these data suggest that the regulation of in 
CRLF2 B-ALL cells by TSLP and IL-7 induced signaling may be involved in adjusting 
the apoptosis versus cell survival switch in these cells. Therefore, we hypothesized that 
small molecule drugs, which target Mcl-l expression can reduce the survival of CRLF2 
B-ALL cells in vitro. To test this hypothesis, we utilized a commercially available Mcl-1 
inhibitor MIM1 to perform dose response experiments and evaluate its in vitro efficacy 
on CRLF2 B-ALL cells using an enzyme-based cell viability, proliferation and function 
test (a metabolic activity test). The MTT assay measures mitochondrial dehydrogenase 
activity in living cells. In most cell types, the total mitochondrial activity is related to the 
number of viable cells, therefore the MTT assay is often used as a drug screening assay 
and as a measure of in vitro cytotoxicity of drugs on cell lines or primary cells [8]. 
CRLF2 B-ALL cells were cultured in culture media with varying concentrations of 
MIM1 for 72 hrs. Cells were harvested and the MTT assay was performed. The results 
from this dose response experiment showed that MIM1 reduced cell viability of CRLF2 
B-ALL cells with an IC50 of 20 uM (Figure 5.1). At 30 uM, cell viability was reduced by 
75%; between 50 uM and 100 uM, there were little to no viable cells present in culture 
(Figure 5.1). These data suggest that MIM1 can induce reduction of CRLF2 B-ALL cell 
viability  by  50%  at  concentrations  at  a  concentration  as  low  as  20  uM  and  that  MIM1’s  
cytotoxic  effects  are  increased  at  concentrations  ≥  30  uM. 
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Figure 5.1: CRLF2 B-ALL cells (MUTZ5) were cultured with different concentrations of 
MIM1 and harvested at 72 hours. Cells were washed, labeled with MTT. Samples were 
read at an absorbance of 570nm. 
 
 
 
NM Small Molecule Drugs Induce Apoptosis in Nalm6 B-ALL Cells In vitro 
In order to identify other promising therapeutic candidates, our lab embarked on a 
collaborative study with Novomedix Drug Company. Novomedix has developed two new 
classes of small molecule drugs that can inhibit biological pathways, which often lead to 
the development of diseases. Novomedix screened a library of 200 compounds that are 
modulators of pathways involved in immune dysfunction and cancer. They identified: 1) 
a tetrazole- 735 and its analog 869 and 2) a pyridine- 785 and its analog 790. 735 and 790 
were subsequently submitted to the National Cancer Institute (NCI) for screening on a 
panel of 60 human tumor cell lines. Both parent drugs were approved for testing, 
indicating that their chemical structures were novel compared to existing anti-cancer 
compounds which were tested by NCI. Novomedix subsequently found that the drugs 
were safe based on in vitro toxicology studies conducted in primary lung fibroblast cells 
and hepatocytes and in vivo toxicology studies conducted in CD-1 mice. Additional 
0 10 20 30 40 50 60 70 80 90 100
0
50
100
150
MUTZ5 MTT assay#2
72 hrs
[MIM1] in uM
%
 V
ia
bi
lit
y
116 
studies were performed to compare the efficacy of traditional chemotherapy drugs 
currently used (e.g vincristine, dexamethasone) to NM drug series and the results 
demonstrated that the NM drugs showed better efficacy on lymphoma cells and other 
diseased cell types. Further mechanistic studies revealed that the NM drug series target 
cell cycle proteins, cyclin D1 and D3. 
Studies have shown that acute lymphoblastic leukemia patients that suffer relapse 
often exhibit increased expression of cell cycle genes and proteins such as the cyclins 
leading to protection from apoptosis, increased proliferation and increased cell survival 
[9]. Therefore we hypothesized that NM drug series can target the cell cycle machinery 
(genes) and reduce the survival of high-risk B-ALL cells. To test this hypothesis, we 
performed drug efficacy studies on chemo-resistant B-ALL cells Nalm6, by assessing 
cellular apoptosis using recommended IC50 concentrations. The IC50 of each drug was 
determined by Novomedix using other cell types and they were as follows: 735 = 300nM; 
785 = 430nM; 869 = 65nM. Nalm6 cells were cultured with NM compounds or DMSO 
control. Cells were then harvested at 48 hrs and the Annexin V/7-AAD assay was 
performed using flow cytometry. Percent apoptosis was determined by combining the 
percent of cells in the early stages of apoptosis (Annexin V+) and the percent of cells in 
the late stages of apoptosis (7-AAD+). 
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Figure 5.2: Nalm6 B-ALL cells were cultured with the Novomedix (NM) compounds 735, 
785 and 869 or DMSO vehicle control. Cells were harvested at 48 hours and stained for 
flow cytometry to detect Annexin V and 7-AAD. Percentages of cells that are living (green) 
or apoptotic cells (Annexin V+7-AAD+ - red) are shown above.  
 
 
Our data showed that all three drugs induced cellular apoptosis when compared to 
cells treated with DMSO, however 735 and 869 were the most potent (Figure 5.2). 785 
induced 25% apoptosis at 430 nM; 735 induced ~43% apoptosis at 300 nM and 869 
induced 50% apoptosis at 65nM. The recommended IC50 for 785 was based on 
assessments completed on other cell types by the company and as such was not the ideal 
IC50 concentration for Nalm6 cells. Therefore further testing is required to determine the 
optimum IC50 for 785 in this system. Our results suggest that a higher dose of 785 would 
be required to show substantial efficacy against Nalm6 cells. Conversely, 869 shows the 
most promise since it required a lower dose to achieve 50% cell death (IC50 nM). These 
data suggest that Novomedix drugs 735 and 869 are promising drug candidates that can 
be used to perform further testing to demonstrate their ability to reduce proliferation and 
induce apoptosis in other subsets of high-risk B-ALL cells including CRLF2 B-ALL.  
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NM Small Molecule Drugs Increase the Survival of NSG Mice Transplanted with 
Chemo-resistant B-ALL Cells In vivo 
After we had determined the efficacy of NM drugs on high-risk B-ALL cells in 
vitro, we investigated the efficacy of NM drugs in vivo by evaluating their effects on the 
survival of NSG mice transplanted with high-risk B-ALL cells (Nalm6). Some of the 
drug analogs for the NM735 and NM785 drug series were potent and successful at 
inducing apoptosis of Nalm6 cells in vitro, however they proved to be toxic to animals 
during in vivo safety testing. Therefore we selected analogs of NM735 and NM785 that 
were successful during in vivo safety testing. Hence for in vivo drug efficacy studies, we 
used NM1123, NM922 and NM911. Typically, NSG mice transplanted with Nalm6 cells 
experience a poor survival outcome due to the aggressiveness of the disease, that is, 
animals die between 18-21 days. Based on our in vitro results, we hypothesized that NM 
drugs will increase the survival of NSG mice transplanted with Nalm6. To test this 
hypothesis, NSG mice were transplanted with 1x107 Nalm6 cells per mouse 
intravenously and 8 days after transplantation, drugs were administered daily via 
intraperitoneal injections for 21 days or until the animals died. NM drugs were 
administered at 25 mg/kg per mouse and vincristine was administered at 0.15 mg/kg per 
mouse. Experimental groups were as follows: untreated, vehicle (DMSO only- negative 
control), vincristine (positive control), NM1123, NM922 and NM911. For all groups, 
n=5 mice except for the untreated group (n=2 mice), and NM1123 (n=6). Drug response 
was assessed by 1) recording visual observations of animals daily and at time/day of 
death and 2) recording the number of days treated animals lived compared to control 
animals.  
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Figure 5.3: A survival curve showing percent survival of animals placed in 6 treatment 
groups. NSG mice were transplanted with 1x107 Nalm6 cells and were treated with four 
different candidate drugs: vincristine- positive control (red), NM1123 (green), NM922 
(pink) and NM911 (blue). The negative controls groups were the no treatment group (grey) 
and vehicle-DMSO group (black).  
 
 
Our results showed that on day 18 (11 days post drug treatment) all untreated 
animals died (Figure 5.3). By day19 (12 days post drug treatment), all vehicle (DMSO 
treated) animals died. This time of survival (18-19 days) is typically observed for NSG 
mice transplanted with Nalm6 cells only. All animals treated with NM911 died by day 18 
(11 days post drug treatment). NM911 treated mice died earlier and on the day of 
untreated mice. Visual observations of these mice revealed that they experienced anal 
bleeding. These observations along with the time of death suggests that in addition to the 
leukemia, NM911 treated animals may have died due to toxic effects of the drug. All NM 
1123 treated animals died by day 22 (15 days post treatment) and the same was observed 
for the vincristine controls. All NM 922 treated animals died by day 25 (18 days post 
treatment). The survival curve summarizes the results and visually compares the data 
obtained from each drug. In summary the data showed that vincristine and NM1123 
increased the survival of Nalm6 NSG mice by 4 days (when compared to the untreated 
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group), while NM922 increased the survival of these mice by 7 days. These in vivo 
studies demonstrate that NM922 showed greater efficacy on Nalm6 cells compared to 
vincristine and other NM drugs. NM922 is therefore a promising drug candidate that can 
be used for further in vitro and in vivo preclinical testing to evaluate its effects on the 
survival of several high-risk B-ALL subsets including CRLF2 B-ALL.  
 
 
Discussion 
With current therapies, ~25% of pediatric B-ALL patients still relapse and they 
experience poor survival outcomes [5, 10]. Within this patient population, genomic 
profiling studies have identified several high-risk B-ALL subtypes that are resistant to 
chemotherapy, including those consisting of alterations in the BCR-ABL, IKZF1 or CRLF2 
genes [5]. The translocation leading to the BCR-ABL+ B-ALL subtype was the first of 
these genetic alterations to be identified and tyrosine kinase inhibitors (TKIs) that 
specifically target the aberrant kinase activity produced by the BCR-ABL genetic defect 
have been developed into drugs [11]. One such drug, Imatinib, when used in combination 
with standard therapy, has increased the survival of children with BCR ABL+ B-ALL from 
~35% to 80% [10, 12]. These studies provided a paradigm for identifying candidate drugs 
that target specific genetic lesions or aberrant signaling pathways associated with high-risk 
B-ALL, and using them in combination with standard therapy to improve survival 
outcomes in children. We used a similar approach by identifying small molecule drugs that 
are known to target molecular lesions/cellular pathways and evaluating the efficacy of 
these drugs on high-risk B-ALL survival.  
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Our results in chapter 4 showed that TSLP induced apoptosis in CRLF2 B-ALL 
cells rendering it as a potential therapeutic to be considered for further preclinical drug 
efficacy testing against CRLF2 B-ALL.  In addition to inducing apoptosis, TSLP also up-
regulated Mcl-1 expression in CRLF2 B-ALL cells in vitro (chapter 4). An increase in Mcl-
1 expression was also observed when CRLF2 B-ALL cells were stimulated with IL-7 
(chapter 4). Mcl-1 has been shown to regulate the survival of many cells and is often up-
regulated in cancer cells [13]. Therefore we assessed the efficacy of the Mcl-1 inhibitor 
MIM1 on CRLF2 high-risk B-ALL and our results showed that MIM1 showed efficacy by 
significantly reducing the survival of these cells. The mechanisms by which MIM1 reduces 
the survival of CRLF2 B-ALL cells remain to be elucidated. Future studies that assess the 
mechanisms  involved  in  MIM1’s  ability  to  inhibit  the  expression  of  Mcl-1 in CRLF2 B-
ALL cells in vitro and the ability of MIM1 to reduce bone marrow disease in vivo are 
required. Additionally, it will be important to assess the effects of other Mcl-1 inhibitors 
such as Maritoclax and other Bcl-2 family inhibitors such as ABT-737 in context of MIM1 
in order to fully validate the therapeutic value of Mcl-1 inhibitors on the CRLF2 B-ALL 
high-risk subset of leukemia. 
In most high-risk B-ALL, cells increase in numbers by undergoing proliferation 
and cyclins have been shown to contribute to this process [14-16]. Thus we assessed the 
efficacy of a new class of small molecule drugs (NM lead series) on chemo-resistant 
high-risk B-ALL. Our results showed that NM735 and NM869 showed efficacy by 
reducing the survival of Nalm6 cells in vitro, while NM 922 and NM1123 (analogs of 
735 and 869) showed in vivo efficacy by increasing the survival of Nalm6 NSG mice 
compared to untreated controls. NM drugs (NM1123 and NM922) showed efficacy that 
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was similar or better than vincristine- a chemotherapy drug that is currently used as part 
of the treatment regimen for patients with high-risk leukemia. Vincristine is considered to 
be among the most potent drugs, however, it is toxic to patients at high concentrations 
[17]. The vincristine effects that we observed in mice was based on daily administration 
of the drug, while in current practice, it is administered to patients once per week. Thus 
the effects we see are at high doses, which would be toxic for patients and would 
undermine the true effects of NM922. Future experiments conducted to evaluate NM 
drugs in context of less frequent dosing (weekly as opposed to daily) of vincristine are 
required in order to optimize the in vivo effects observed for NM922 in high-risk B-ALL 
cells. Additionally, NM drug series should be tested on other subsets of high-risk B-ALL 
including CRLF2 B-ALL cells to fully evaluate its therapeutic value.  
Improved remission rates in recent years are primarily due to the administration of 
higher doses of standard chemotherapy [7]. However, these higher doses have resulted in 
increased toxicity and side effects for patients and to compound this, they have been 
ineffective in reducing the relapse-rate of CRLF2 B-ALL and other high-risk B-ALL [7, 
18, 19]. Targeted therapy is therefore advantageous in that it can decrease toxicity by 
targeting distinct cell lineages, cell cycle proteins or dysfunctional tumor suppressors 
which all contribute to relapse but are often not targeted using current treatment 
regimens. Our studies provide evidence of the efficacy of two categories of drugs, which 
target molecular lesions and oncogenic cellular processes that can be used for further 
preclinical testing on CRLF2 B-ALL and other high-risk B-ALL. They offer the potential 
to be used in combination with reduced doses of standard therapy while increasing 
overall efficacy of treatment in high-risk B-ALL.  
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CHAPTER SIX 
DISCUSSION 
 
Summary of Chapter Findings and Relevance to the Leukemia Field 
The objective of my dissertation studies was to elucidate the TSLP-CRLF2-
mediated cellular and molecular mechanisms that contribute to high-risk CRLF2 B-ALL 
and to evaluate promising drug candidates to target CRLF2 B-ALL and other high-risk 
B-ALL. Our working hypothesis was that TSLP contributes to CRLF2 B-ALL by 
increasing proliferation and/or survival of leukemia cells via regulation of genes 
downstream of CRLF2 pathway activation. To accomplish our objective, we developed 
three aims. The first aim was to optimize the novel hTSLP+/hTSLP- xenograft model for 
use in defining the role of TSLP in CRLF2 B-ALL; the second aim was to identify TSLP-
induced cellular and molecular mechanisms that contribute to CRLF2 B-ALL; and the 
third aim was to assess candidate  drugs’  efficacy  against  high-risk B-ALL.  
The molecular mechanisms that contribute to the development and maintenance 
of high-risk B-ALL that are linked to the recently discovered CRLF2 genetic defect 
remain unclear and despite the success of current therapeutic strategies with some high-
risk B-ALL, CRLF2 B-ALL patients still experience at a 65% relapse rate [1]. Research 
groups that currently study CRLF2 B-ALL are focused primarily on genomic profiling 
studies, the identification of molecular lesions within CRLF2 pathways such as JAK2 
mutations and aberrant signaling of the JAK-STAT and mTOR pathways [1-7]. This 
current direction of the field is based upon studies conducted using a BaF3 model system- 
an IL-3-dependent murine cell line transduced with mutant JAK and/or mutant CRLF2 
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[5, 6]. In these studies, researchers demonstrated that cells that overexpress CRLF2 (due 
to the presence of CRLF2 genetic defects) and consist of mutations in JAK2 showed 
constitutive activation of JAK/STAT signaling and cytokine independent growth, which 
was enough to transform cells [5, 6, 8]. These results were not observed in BaF3 cells 
that harbored CRLF2 overexpression alone or in cells with JAK2 mutations alone [5]. 
Further co-immunoprecipitation studies demonstrated that human CRLF2 and 
phosphorylated mutant JAK2 interact physically [5]. Therefore the current hypothesis in 
the field is that CRLF2 and JAK2 cooperate to lead to leukemogenesis [9, 10] and the 
contributions of TSLP-the endogenous ligand for CRLF2- to the disease mechanisms of 
CRLF2 B-ALL remain to be elucidated.  
Our approach to understanding CRLF2 B-ALL disease mechanisms was to 
determine the effects of TSLP on the disease. To do this, as proposed in aim 1, first we 
developed and optimized a novel hTSLP+/hTSLP- model system described in chapter 2. 
The rationale for developing this model was based on the fact that mouse TSLP does not 
activate human CRLF2 BALL cells in vitro. To confirm that the human TSLP produced 
in our model acts on human cells; using the human TSLP in vivo model system, we 
demonstrated that human TSLP signals produced in the model activates human CRLF2 
on normal B-cells and increases the number of CD19+ B-cells in the bone marrow 
(chapter 2). It is established in the field that TSLP induces proliferation of normal murine 
B-cells and it was more recently shown that TSLP induces proliferation of human fetal B-
cells in vitro [11, 12]. Therefore, the ability of the human TSLP produced in our model to 
expand normal B-cells confirmed the previously published findings and provided the first 
in vivo data, all of which served as a validation of the model. Next we confirmed that 
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TSLP produced in the model also activates CRLF2 B-ALL cells in vivo. Our results 
showed that the TSLP produced in the model up-regulated one of the main TSLP-CRLF2 
pathways, the mTOR pathway, in CRLF2 B-ALL cells in vivo [13]. Other groups have 
shown that TSLP activates the mTOR pathway in pre-B ALL cells and in CRLF2 B-ALL 
cells in vitro [7, 14, 15]. Thus, the ability of the human TSLP produced in our model to 
induce the mTOR pathway in CRLF2 B-ALL cells in vivo provided additional validation 
for the hTSLP model system. Moreover, this is the first study to produce a 
hTSLP+/hTSLP- human-mouse xenograft system and it is the first demonstration of the 
use of this system to induce B-lymphopoiesis in normal B-cells (chapters 2, 3) and 
activate TSLP-regulated pathways in CRLF2 B-ALL cells in vivo (chapter 2). 
In order to further delineate the mechanisms of TSLP-induced signaling in 
CRLF2 B-ALL cells as proposed in aim 2, our approach was to first understand the 
TSLP-induced mechanisms in normal B-cells and then use this as a framework for 
evaluating and understanding the contributions of TSLP to the disease mechanisms 
involved in CRLF2 B-ALL cells. Using the hTSLP+/hTSLP- model system, we 
demonstrated that TSLP up-regulates Mcl-1 and induces proliferation of CD19–
CD34+IL7RD+ progenitors, resulting in a 3-4-fold expansion of the CD34+ pro-B cells; 
and that this expansion is maintained during the subsequent stages of B-cell development 
(chapter 3). Additionally, the data showed that the observed increases in B-cell numbers 
were due not only to proliferation, but also due to protection from apoptosis (chapter 3). 
Though the roles of TSLP and IL-7 have been well studied in murine B-cell 
development, the roles of both cytokines in human B-cell development remained 
controversial. Our studies are significant in that the hTSLP+/hTSLP- model system 
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provides both cytokines (human TSLP which is species-specific and murine IL-7 which 
is cross-reactive) allowing the opportunity to study the effects of TSLP in context of IL-7 
for the first time in vivo. Our studies were also significant in that they introduced for the 
first time a survival role for TSLP in human B-cells, which is distinctly different from the 
roles of IL-7  (chapter  3).  Moreover,  TSLP’s  effect  on  normal  B-cells provides evidence 
that supports our hypothesis stated in the first paragraph of this discussion.  
After confirming that the human TSLP in our model can activate normal human 
B-cells, which express low levels of CRLF2; we used the hTSLP+/hTSLP- in vivo model 
system to evaluate the effects of TSLP on CRLF2 B-ALL cells, which express high 
levels of CRLF2. Our results showed that at low levels of TSLP, there was no difference 
in the percent of CRLF2 B-ALL cells that were engrafted in the bone marrow of PDXs 
(chapter 4). However, assessment of the percent of viable CD19+ cells showed that of the 
cells that were engrafted, there was an increase in the percent of apoptotic cells in the +T 
mice compared to the –T mice. When higher levels of TSLP were added, there was little 
to no leukemia cells engrafted in the BM (chapter 4). Microarray results comparing gene 
expression patterns from CRLF2 B-ALL cells expanded in +T mice compared to –T 
mice, showed that TSLP up-regulates genes that are involved in cell death and survival 
functions of the cell (chapter 4). Additional genetic data showed that TSLP also up-
regulates genes that are involved in cell death and survival signaling pathways; the cell 
death pathways being more significant (chapter 4). The genetic data provided evidence to 
support the in vivo data showing that TSLP regulates both cell death and survival 
mechanisms, but primarily induces apoptosis in CRLF2 B-ALL cells in vivo. Therefore 
we performed in vitro experiments  to  further  confirm  TSLP’s  effects  on  these  cells. This 
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was accomplished by assessing the survival of cells stimulated with TSLP in vitro. Our 
results showed that TSLP increased Mcl-1 expression and maintained cell survival at 
early time points, but later induced apoptosis in CRLF2 B-ALL cells (chapter 4). These 
studies are the first to evaluate the long-term functional effects of TSLP on CRLF2 B-
ALL cells in vitro and more importantly in vivo thereby introducing a novel role for 
TSLP as a possible therapeutic candidate. Interestingly, the data showing that TSLP 
induces apoptosis in CRLF2 B-ALL does not support our hypothesis stated in paragraph 
1 of this discussion. Therefore future studies that further elucidate the mechanisms by 
which TSLP exerts its effects are required to fully understand its role in the disease and 
its therapeutic value. We also identified Mcl-1 as a potential molecular target that can be 
considered for inhibitor studies against CRLF2 B-ALL.  
Patients diagnosed with CRLF2 B-ALL still experience higher rates of relapse 
and currently no targeted treatment exists [1]. Studies have recommended the use of JAK 
inhibitors in clinical trials for the treatment of Ph-like ALL, including CRLF2 B-ALL, 
however preclinical and clinical testing are still underway and not all CRLF2 leukemias 
harbor JAK mutations [16, 17]. Therefore there is a need for the testing of drug 
candidates that the offer potential to induce cytotoxic effects on CRLF2 B-ALL cells. We 
addressed this need in aim 3, which was accomplished by conducting drug efficacy 
studies against CRLF2 B-ALL and other high-risk B-ALL cells (chapter 5). Results 
showing that TSLP induces apoptosis in CRLF2 B-ALL cells require further testing, but 
provide evidence that TSLP can be considered as a lucrative potential therapy for CRLF2 
B-ALL (chapter 4). Based on the results which showed that TSLP also increased the 
expression of Mcl-1, a Bcl-2 family member which functions to increase cell survival, we 
130 
evaluated the efficacy of the Mcl-1 inhibitor MIM1 on CRLF2 B-ALL cells in vitro 
(chapter 5). Our results showed that MIM1 reduced the viability of CRLF2 B-ALL cells 
and showed cytotoxic effects as MIM1’s concentration was increased; proposing MIM1 
as another drug candidate that can be used for further efficacy studies against CRLF2 B-
ALL (chapter 5). In vitro and in vivo drug efficacy studies were also performed on 
another subset of high-risk B-ALL that is chemo-resistant using a new class of drugs 
(NM drug series), which inhibit cyclin-D-mediated proliferation in cells. The results 
showed that NM735 and NM869 showed efficacy against chemo-resistant B-ALL cells in 
vitro and NM922 showed efficacy against these same cells in vivo (chapter 5). The NM 
series are potential candidates that can be used for further efficacy studies against chemo-
resistant B-ALL and other high-risk B-ALL such as CRLF2 B-ALL. Taken together, we 
have identified 3 potential candidates that can be used for further preclinical efficacy 
studies against CRLF2 B-ALL.  
 
Conclusions and Future Implications 
Overall, our studies were significant because 1) we were able to develop and 
optimize a novel xenograft model that provides human TSLP in vivo; 2) we used the 
human TSLP model to further investigate the TSLP-induced mechanisms involved in 
CRLF2 B-ALL (against a backdrop of normal B-lymphopoeisis); 3) we identified drug 
candidates that can be furthered evaluated as potential therapies for the treatment of 
CRLF2 B-ALL. Our studies provide new data that will contribute to a new understanding 
in the field of CRLF2 B-ALL disease mechanisms in context of TSLP. There are several 
points to consider as we assimilate this new data. First, it is difficult to study the role of 
131 
TSLP in CRLF2 B-ALL in vivo because current xenograft models that are used to study 
pediatric acute lymphoblastic leukemia lack human TSLP. PDXs are successful because 
most mouse cytokines are cross-reactive, having the ability to act on human leukemia 
cells and provide the growth signals that are necessary for these cells to expand in vivo 
[18]. However, TSLP is species specific [18]. The hTSLP+/hTSLP- model described in 
these studies provides the human TSLP that is required to design experiments that 
address the TSLP-mediated disease mechanisms of CRLF2 B-ALL and conduct 
preclinical testing of potential therapeutic candidates. Second, the TSLP-mediated 
signaling and cellular functions in CRLF2 B-ALL  are  different  from  TSLP’s  functions in 
normal cells. In normal B-cells, TSLP activates the JAK/STAT pathway and induces 
proliferation [12]. In CRLF2 B-ALL cells, basal levels of pJAK2, pSTAT5 and pS6 are 
present in the absence of TSLP, which is hypothesized as contributing to the constitutive 
activation of the JAK/STAT pathway (aberrant signaling) and leading to enhanced 
leukemia cell growth [6, 19]. Further, CRLF2 B-ALL cells stimulated with TSLP show 
increases in pSTAT5, and pS6 compared to untreated cells that express basal levels of 
pSTAT5, suggesting further increases in the activation of JAK/STAT and 
PI3K/AKT/mTOR pathway [7]. However, our functional studies (in vitro and in vivo) 
described in the previous chapters, show that though there is increased pSTAT5 and pS6 
in the presence of TSLP with which we would expect to see increased proliferation 
compared to normal B-cells or untreated CRLF2 B-ALL cells, instead we observed the 
induction of apoptosis (chapters 2 and 4). Our studies show that stimulating CRLF2 B-
ALL cells with TSLP reduces the survival of these cells by inducing apoptosis, 
suggesting that the TSLP-mediated signaling is not only different from what occurs in 
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normal B-cells, but is also different from what occurs in the leukemia cells in the absence 
of TSLP (Figure 6). This finding is paradigm shifting and has major future implications 
for understanding the disease mechanism of CRLF2 B-ALL and the designing of 
treatment strategies for the treatment of the disease. 
Therefore the major questions that remain to be addressed are: 1) what 
mechanisms are involved in the TSLP-induced apoptosis of CRLF2 B-ALL?; 2) to what 
end does TSLP induce apoptosis in CRLF2 B-ALL cells?; 3) is TSLP inducing apoptosis 
to eradicate cancer cells thereby rendering it as a potential therapeutic candidate for the 
treatment of CRLF2 B-ALL?; 4) what is the therapeutic value of TSLP in relation to the 
treatment of CRLF2 B-ALL? 5) or is it a mechanism used by TSLP to regulate the 
cellular apoptosis versus cell survival switch in order to produce resilient clones of cells 
that can resist chemotherapy treatment and later contribute to MRD and relapse? Future 
studies that are designed to answer these questions will provide a basis for fully 
elucidating the involvement of TSLP in the initiation, maintenance and/or progression of 
CRLF2 B-ALL. 
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Figure 6: TSLP-induced Mechanisms in CRLF2 B-ALL. This cartoon serves as a visual 
illustration to show the differences in CRLF2 B-ALL mechanisms in the absence and 
presence of TSLP.  
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APPENDIX A (CHAPTER 2) 
SUPPLEMENTAL MATERIALS 
Supplemental Methods 
Cell Culture Media 
 
MUTZ5 and MHH-CALL4 were maintained in RPMI 1640 medium (Irvine 
Scientific, Santa Ana, CA) supplemented with penicillin/streptomycin, L-glutamine, 50 
uM 2-ME and 20% FBS (Omega Scientific, Tarzana, CA). This media was also used for 
in vitro cultures with and without TSLP (both for phospho-flow assays and for gene 
expression profiling in response to TSLP). HS27 stroma were maintained in RPMI 1640 
medium (Irvine Scientific) supplemented with penicillin/streptomycin, L-glutamine, 50 
uM 2-ME and 10% FBS (Omega Scientific). 
 
Flow Cytometry 
 
Cells were prepared for surface antigen detection and assessed by flow cytometry 
using protocols described in companion paper. Dead cells were identified using fixable 
viability dye as described in companion paper. Specific antibody clones and conjugates 
are shown below.  
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Table 2.  List of Antibodies, Clones and Manufacturer Information 1 (chapter 2). 
 
Antibody Clone Manufacturer 
Ig  κ  light  chain  FITC G20-193 BD Pharmingen (San Jose, CA) 
Ig  λ  light  chain  FITC JDC-12 
Anti-phospho STAT5 (pY694) PE 47/Stat5 
(pY694) 
BD Biosciences (San Jose, CA 
Anti-Phospho AKT (pS473) Alexa Fluor 488 M89-61 
Anti-Phospho S6 (pS235/S236) Alexa Fluor 
488 
N7-548 
CD34 PerCP 581 BioLegend (San Diego, CA) 
CD19 APC HIB19 
TSLPR APC 1B4 
CD19 APC HIB19 eBioscience (San Diego, CA) 
CD19 PE.Cy7  SJ25C1 
CD45 PE.Cy7  HI30 
Anti-Mouse CD45 FITC 30F11 Miltenyi Biotec (Auburn, CA) 
CD19 APC LT19 
CD127 PE (IL-7Ra) MB15-
18C9 
 
 
 
Phospho-flow Cytometry Staining 
 
Human CRLF2 B-ALL cell lines were harvested from continuous culture and 
primary CRLF2 B-ALL cells were obtained as BM from patient-derived xenografts. Cells 
were rested in culture without cytokines for 2 hrs, and then cultured with mTSLP, hTSLP 
or no cytokine for 30 mins (S6 and AKT) or 1 hour (STAT5). Cells were then harvested 
and stained with antibody to phosphorylated STAT5 (pSTAT5), AKT (pAKT) or S6 
(pS6) as previously described for STAT5 (1). Primary CRLF2 B-ALL patient-derived 
samples were also stained with CD19 APC prior to fixation and permeabilization for 
detection of phospho proteins and CD19+ cells were gated for phospho-flow cytometry 
plots.  
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ELISA Assays of TSLP 
 
Concentrations of hTSLP in the supernatant of transduced HS27 stromal culture 
and in sera collected from NSG mice injected with transduced stroma were measured 
using the Human TSLP ELISA MAX Kit (BioLegend, San Diego, CA). Stromal cell 
supernatants were harvested from confluent flasks when stromal cells were passaged 
(typically two times per week) and sera was obtained from mice at weekly time points at 
the time of weekly stromal cell injection. Data was collected using the uQuant microplate 
spectrophotometer (BioTek Instruments Inc., Winooski, VT) and analyzed using the KC 
Junior, version 1.6 (BioTek Instruments, Inc., Winooski, VT) 
 
Lentiviral Vector and TSLP-expressing Human Stromal Cells 
 
TSLP vector was generated using standard molecular cloning techniques with 
complementary DNA encoding human TSLP (purchased from Thermo Scientific Open 
Biosystems). In this vector, the EF-1α  promoter  was  used  to  drive  TSLP  expression.  A  
control vector with GFP was also generated. The lentiviral vector packaging and titering 
were performed as previously described (2). In brief, VSV-G–pseudotyped lentiviral 
vectors were prepared by calcium phosphate–mediated 3-plasmid transfection of 293T 
cells. Briefly, 27 µg transfer vector construct, 17.5 µg second-generation gag-pol 
packaging construct pCMV.R8.74, and 9.5 µg VSV-G expression construct pMD2.G 
were used for transfection of 12x106 293T cells overnight in 25 ml DMEM with 10% 
fetal bovine serum. The cells were treated with 10 mM sodium butyrate during the first of 
three 12-hour vector supernatant collections. The supernatant was filtered through 0.22-
µm-pore-size filters and concentrated 100-fold by ultracentrifugation before freezing and 
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storing at –80° C. All vector stocks were titered by transducing HT1080 cells with 
analysis for GFP expression by flow cytometry or real-time PCR.  
 
Processing of Samples from Xenograft Mice 
 
Flow cytometry analysis of peripheral blood (PB) was used to establish 
chimerism with human cells prior to euthanasia. PB was collected using tail-tip excision 
(tail nick) and placed into a microtainer serum separator tube (BD Gold, 200/cs). Samples 
were centrifuged at 1500 rpm for 15 mins. Serum was removed for ELISA analysis. 
Blood cells were subjected to red blood cell lysis (3) and remaining white blood cells 
were stained for human surface markers. NSG mice were euthanized 5-7 weeks after CB 
CD34+ transplantation or 9 weeks after CRLF2 B-ALL transplantation. On the day of 
euthanasia fresh Bone Marrow (BM), spleen and PB were harvested. Single cell 
suspensions were obtained from the BM by using 26g syringe and PBS to flush the 
femora and humeri and by filtering cells with a 70 micron cell strainer (BD Biosciences, 
San Jose, CA). Cells obtained from all tissues were stained immediately for flow 
cytometry analysis or were frozen for future use. 
 
Microarray Analysis of Gene Expression in CRLF2 B-ALL Cells 
 
Mice engineered to be +T and –T by stromal cell injection were transplanted with 
primary CRLF2 B-ALL cells from a Hispanic pediatric patient. Following transplant, 
mice received weekly intraperitoneal injection of 5X106 +T or –T stroma from 
Transduction 1 (see Results section). Nine weeks post transplant, BM was harvested and 
frozen for later use. For microarray to evaluate in vivo TSLP-induced changes in gene 
expression, xenograft BM was thawed and human B-ALL cells were isolated by 
magnetic separation using the Human CD19 microbead kit (Miltenyi Biotec, Inc., San 
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Diego,  CA)  according  to  manufacturer’s  protocol  and  rapidly  frozen  on  dry  ice  (Samples  
E1-E3 and F1-F3 described below).  For microarray to evaluate in vitro TSLP-induced 
changes in gene expression (Fig. 4), xenograft BM was thawed and cultured in vitro for 3 
days with TSLP at 15ng/ml or without TSLP and with neutralizing anti-TSLP antibody 
(R&D Systems, Minneapolis, MN) or control antibody (Jackson ImmunoResearch). 
Following culture, cells were harvested and thawed and human B-ALL cells were 
isolated by magnetic separation using the Human CD19 Microbead Kit according to 
manufacturer’s  protocol  and  rapidly  frozen  on  dry  ice  (samples  A1-A3, B1-B3, C1-C3 
and D1-D3 as described below). Frozen cells were shipped to Miltenyi Biotec (Miltenyi 
Genomic Services) for RNA isolation, sample preparation, whole genome microarray, 
and discriminatory gene analysis (DGA) as follows:  
Total RNA Isolation. Human total RNA was isolated using the NucleoSpin® 
RNA kit (Macherey-Nagel, Bethlehem, PA). RNA quality and integrity were determined 
using the Agilent RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). RNA was quantified by measuring A260nm on the ND-
1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
RNA Amplification and Labelling. Sample labelling was performed as detailed in 
the  “One-Color Microarray-Based Gene Expression Analysis protocol (version 6.6, part 
number G4140-90040). Briefly, 50 ng RNA for the samples from groups A, B, E and F, 
10 ng RNA for the samples of group C and D, and the complete available amount of 
RNA for the samples C3 and D1 was used for the amplification and labelling step using 
the Agilent Low Input Quick Amp Labelling Kit (Agilent Technologies). Yields of 
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cRNA and the dye-incorporation rate were measured with the ND-1000 
Spectrophotometer (NanoDrop Technologies).  
 
Table 3.  Microarray Sample Key. 
 
Sample Source of Cells In vitro Culture, Condition 
A1, A2, A3 CRLF2 B-ALL cells from +T mice Yes, +TSLP 
B1, B2, B3 CRLF2 B-ALL cells from +T mice Yes, –TSLP 
C1, C2, C3 CRLF2 B-ALL cells from –T mice Yes, +TSLP 
D1, D2, D3 CRLF2 B-ALL cells from –T mice Yes, –TSLP 
E1, E2, E3 CRLF2 B-ALL cells from +T mice No, ---------- 
F1, F2, F3 CRLF2 B-ALL cells from –T mice No, ---------- 
 
 
Hybridization of Agilent Whole Human Genome Oligo Microarrays. The 
hybridization  procedure  was  performed  according  to  the  “One-Color Microarray-Based 
Gene Expression Analysis protocol (version 6.6, part number G4140-90040) using the 
Agilent Gene Expression Hybridization Kit (Agilent Technologies). Briefly, 0.6 µg Cy3-
labeled fragmented cRNA in hybridization buffer was hybridized overnight (17 hours, 65 
°C) to Agilent Whole Human Genome Oligo Microarrays 8x60K v2 (AMADID 039494) 
using  Agilent’s  recommended  hybridization  chamber  and  oven.  Following  hybridization,  
the microarrays were washed once with the Agilent Gene Expression Wash Buffer 1 for 1 
min at room temperature followed by a second wash with preheated Agilent Gene 
Expression Wash Buffer 2 (37 °C) for 1 min.  
Scanning and Data Analysis: Fluorescence signals of the hybridized Agilent 
Microarrays  were  detected  using  Agilent’s  Microarray  Scanner  System  G2505C  (Agilent  
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Technologies). The Agilent Feature Extraction Software (FES) 10.7.3.1 was used to read 
out and process the microarray image files. 
Discriminatory Gene Expression Analysis. After probe summarization, quantile 
normalization and log2 transformation, differentially expressed genes were identified by 
a combination of effect size and statistical significance. For the analysis of the individual 
comparisons, only reporters with an at least two-fold median up- or downregulation in +T 
samples compared to –T samples and an adjusted p-value  (Student’s  t-test, two-tailed, 
equal variance, Benjamini-Hochberg  correction  for  multiple  testing)  p≤0.05  were  
considered relevant. In an additional filtering step, only Agilent reporters with signal 
intensity values significantly above local background (p<0.01 as calculated by the 
Rosetta Resolver® gene expression data analysis system) in at least two samples of the 
group with higher median expression were selected (4). All microarray data reported in 
this  publication  were  deposited  in  the  NCBI’s  Gene  Expression  Omnibus  at  National  
Center for Biotechnology Information and are accessible via the GEO series accession 
number GSE65274.  
 
Real Time Quantitative RT-PCR 
 
Expression of select genes observed in microarray results was validated using 
quantitative reverse transcriptase - polymerase chain reaction (qRT-PCR) using primers 
shown  below.    Total  RNA  (2.0μg)  was  reverse  transcribed  using  poly  d(T)20  primers  and  
SuperScript II reverse transcriptase (Life Technologies, Grand Island, NY). The resulting 
cDNAs were used for qRT-PCR analysis of their mRNA levels on a StepOne Plus 7500 
Real-time PCR system (Applied Bioscience Inc., Foster City, CA) using specific primers 
for each gene (see supplemental table 2 for primer sequences) following the 
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manufacturer's instructions. The fluorescence threshold value was calculated and 
normalized to the values of 18s rRNA. The fold change in mRNA expression of genes 
between the TSLP-treated W31 cell group versus untreated group was achieved by the 
ratio of fluorescence threshold value in the treated groups versus that of the untreated 
group. The fold change for each gene was paired with that of microarray analysis.  Linear 
regression analysis of the fold change versus that of microarray was performed with 
Origin 6.0. The graph shows the best-fit line, the formula for the best-fit line (Y = a + 
bX), its correlation coefficient (r), and the probability (P) that the r value is a false 
positive. 
 
Table 4.  Primer List for Genes Validated by qRT-PCR 
 
Gene Forward Primer Reverse Primer 
BIVM 5’-GGCCAGAGGCAATGCAAAG                                     5’-TGAGGTCTAATACTTTCCGCTGT 
PTH2 5’-CTGGTTCTCCACAGGTGATG                                    5’-CATGTACGAGTTCAGCCACT 
FOSL2 5’-AACACCCTGTTTCCTCTCCG                                   5’-ATCTACCCGGAATTTCTGCGG 
RAMP1 5’-GCAGGACCATCAGGAGCTACA                              5’-GCCTACACAATGCCCTCAGTG 
SLC4A8 5’-TGGGTCCAGTAGGGAAAGGT                               5’-ACCGTCACCTGGTCTAGGAA 
NR4A2 5’-GTAACTCGGCTGAAGCCATGC 5’-GTCGTAGCCTGTGCTGTAGTT 
KCNH8 5’- GCAAGATCAATTTGCATCCACTAT                        5’- AAGGCAGGGCAGCGATTA 
THSD7A 5’- CCATCTCGAGTCTTTGTTCACATT 5’- CATTTGGGAATTGTGCTTCTCA 
RAB26 5’-CCAGGCCCTTCTGACTTTGT 5’-CTGCTTGTTGGGACTGTTGC 
RGS1 5’-CTCCCTGGGTGAACAGCTTG 5’-GCTTCTTCAACTCTGCGCCT 
NELL1 5’-GATATGAAGCCACCCGTGTT 5’-CTGAAGGTCAGGGTCCATCC 
MDF1 5’-GAAGTTGCAGACACACCCATCTC 5’-GTCCAGGACGATGTTGCACAG 
KREMEN2 5’-TGAGGACCCAGAGGCCC 5’-CAGACAGCTCCCCCAATCG 
CPNE8 5’-CGCCTCCTCCCAATATGGAC                                 5’-ATTTCTGCAGGACACGGACA 
 
 
 
Gene Set Enrichment Analysis 
 
Microarray data was evaluated at the level of gene sets to define and quantitate 
trends in gene expression similar to published data. Ranked gene lists were created and 
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submitted to the online public repository provided by the BROAD Institute for Gene Set 
Enrichment Analysis (GSEA) (5, 6) to evaluate Oncogenic Signatures that are enriched in 
CRLF2 B-ALL cells expanded in +T as compared to –T mice 
(www.broadinstitute.org/gsea).  
 
 
Ingenuity Pathway Analysis 
 
The complete list of differentially expressed genes obtained from microarray 
datasets were uploaded and analyzed using the Ingenuity Pathway Analysis tool (IPA; 
Ingenuity Systems, Redwood City, CA) to identify significant biological pathways that 
are up-regulated in CRLF2 B-ALL cells expanded in +T compared to –T mice. The 
pathways  were  identified  using  the  “Canonical  Pathway”  feature  of  IPA.  The  activity  of  a  
pathway was deemed significant if its p-value is less than or equal to 0.05 and is 
calculated using the right-tailed Fisher Exact Test. 
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Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Expression of CRLF2 and IL-7RD on normal human B cell precursors and 
CRLF2 B-ALL harvested from xenograft mice. (A) Bone marrow was harvested from 
xenograft mice transplanted with human CD34+ cord blood cells or and stained for flow 
cytometry. Plotted is CRLF2 and IL-7Ra expression on B cell precursors (hCD19+ and Ig 
kappa & lambda–) B) Bone marrow was harvested from a patient-derived xenograft 
generated using the primary CRLF2 B-ALL sample shown in Fig. 1B, right panel. Plotted 
is the CRLF2 and IL-7Ra on human CRLF2 B-ALL (hCD19+) cells.  
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Supplemental Tables 
 
 
Table 5. 
 
qRT-PCR validation of genes that are differentially regulated in CRLF2 B-ALL cells 
expanded in +T as compared to –T xenograft mice. The table shows the list of genes 
that were selected from the microarray dataset for validation by qRT-PCR analysis and 
their respective fold changes as determined by microarray and by qRT-PCR. The first 7 
genes are up-regulated, while the last 7 genes are down-regulated. 
 
Gene Microarray  
(fold change) 
qRT-PCR  
(fold change) 
BIVM 4.440 6.907 
PTH2 3.477 2.784 
FOSL2 2.793 1.843 
RAMP1 2.725 2.227 
SLC4A8 2.628 6.417 
NR4A2 2.138 3.548 
KCNH8 2.154 2.355 
   
THSD7A –3.628 –6.648 
RAB26 –2.727 –2.726 
RGS1 –2.749 –2.498 
NELL1 –3.586 –3.143 
MDF1 –2.168 –7.621 
KREMEN2 –2.336 –2.003 
CPNE8 –3.008 –4.695 
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Table 6: Genes regulated downstream of mTOR signaling. GSEA data summary table 
shows genes that are part of the mTOR gene set which were enriched in CRLF2 B-ALL 
cells expanded in +T mice as compared to –T mice. Genes are listed in order of increasing 
enrichment score (ES).  
Gene Symbol Rank in  
Gene List 
Rank 
Metric Score 
Running ES Core 
Enrichment 
ECHDC2 148 0.690 0.0435 Yes 
FBLN5 176 0.662 0.0935 Yes 
BIN2 275 0.560 0.1304 Yes 
CD1A 291 0.548 0.1723 Yes 
CD1B 463 0.451 0.1955 Yes 
EFHC1 721 0.361 0.2054 Yes 
POLH 800 0.343 0.2268 Yes 
SPRY1 946 0.304 0.2402 Yes  
GPA33 973 0.296 0.2616 Yes 
ZNF14 1165 0.252 0.2677 Yes 
H1F0 1219 0.242 0.2829 Yes 
ZBTB20 1232 0.238 0.3008 Yes 
ANXA5 1238 0.236 0.3189 Yes 
PCNXL2 1293 0.224 0.3326 Yes 
CBX7 1405 0.205 0.3407 Yes 
BAALC 1442 0.198 0.3537 Yes 
NFE2 1606 0.172 0.3555 Yes 
RAG1 1610 0.171 0.3687 Yes 
PBXIP1 1705 0.159 0.3745 Yes 
HBP1 1721 0.157 0.3857 Yes 
TNRC6B 1854 0.139 0.3872 Yes 
SLC2A11 1901 0.134 0.3945 Yes 
GIMAP6 1966 0.129 0.4000 Yes 
MME 1976 0.128 0.4094 Yes 
HHAT 1984 0.127 0.4189 Yes 
GALNT7 2003 0.125 0.4273 Yes 
TPM2 2041 0.121 0.4342 Yes 
TXNIP 2069 0.119 0.4415 Yes 
GCC2 2090 0.117 0.4493 Yes 
REL 2151 0.112 0.4538 Yes 
SUV420H1 2285 0.100 0.4521 Yes 
ZNF673 2306 0.099 0.4584 Yes 
SENP7 2310 0.098 0.4659 Yes 
SLC35D1 2381 0.094 0.4683 Yes 
PNRC1 2432 0.091 0.4719 Yes 
TRIOBP 2437 0.091 0.4787 Yes 
SYNE2 2453 0.090 0.4847 Yes 
YPEL5 2507 0.087 0.4878 Yes 
CBFA2T3 2519 0.087 0.4938 Yes 
ZNF682 2527 0.087 0.5001 Yes 
DNTT 2535 0.086 0.5064 Yes 
CD1E 2539 0.086 0.5129 Yes 
RAG2 2577 0.084 0.5168 Yes 
CHIC2 2670 0.079 0.5164 Yes 
RCOR3 2674 0.079 0.5224 Yes 
KIAA0355 2741 0.076 0.5236 Yes 
TPP1 2818 0.073 0.5239 Yes 
DMXL1 2834 0.072 0.5284 Yes 
WDR45 2848 0.071 0.5331 Yes 
ZXDC 2875 0.070 0.5367 Yes 
CCNG2 2913 0.068 0.5394 Yes 
MARCH8 2986 0.066 0.5394 Yes 
BCOR 3024 0.064 0.5418 Yes 
ZNF180 3026 0.064 0.5468 Yes 
HIST1H2AC 3058 0.063 0.5495 Yes 
SLC23A2 3078 0.063 0.5531 Yes 
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APPENDIX B (CHAPTER 3) 
SUPPLEMENTAL MATERIALS 
Supplemental Methods 
 
Human Samples 
 
Umbilical cord blood (CB) and bone marrow (BM) were obtained in accordance 
with protocols approved by the Loma Linda University Institutional Review Board (IRB) 
and with the Helsinki Declaration of 1975, as revised in 2008. Umbilical cord blood (CB) 
was obtained from placentas after caesarean section delivery of full-term neonates at 
Loma Linda University Medical Center. Mononuclear cells were isolated using Ficoll-
Paque Plus (GE Healthcare Bio-Sciences, AB) or by red blood cell (RBC) lysis (1). 
CD34+ cells were isolated by magnetic separation with CD34+ microbeads (Miltenyi 
Biotec, Auburn, CA) and stored in liquid nitrogen for subsequent use. Pediatric bone 
marrow (BM) samples were obtained as waste samples remaining after clinical 
procedures under an LLU Institutional Review Board (IRB) approved protocol. Adult 
BM and stromal cells were purchased from Lonza Inc. (Walkersville, MD). Stromal cells 
were isolated from pediatric and adult BM as previously described (2) and maintained in 
IMDM medium supplemented with 15% horse serum, 15% FBS, hydrocortisone, 2-
mercaptoethanol, penicillin-streptomycin and L-glutamine.  
 
In vitro Co-cultures  
 
Human only in vitro co-cultures were initiated as previously described (3). 
Briefly, CB CD34+ cells were seeded onto pre-plated primary human BM stromal cells, 
at 10,000 to 20,000 cells per well in 96-well plates. For some experiments, numbers were 
scaled up to give equivalent cell densities in 6-well and 12-well plates. Cultures were 
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maintained in RPMI 1640 medium (Irvine Scientific, Santa Ana, CA) supplemented with 
penicillin/streptomycin, L-glutamine, 50 uM 2-mercaptoethanol and 5 % human AB 
serum lot tested to support human B cell production (Omega Scientific, Tarzana, CA). 
All cultures, including control, were supplemented with IL-3 (1 ng/ml; first week only) 
and Flt-3 Ligand (1 ng/ml, continuously). For selective cytokine stimulation TSLP (10 
ng/ml) and/or IL-7 (5 ng/ml) or no cytokines (control cultures) were added. All cytokines 
were from R&D Systems Inc. (Minneapolis, MN). If TSLP or IL-7 was not added, 
cultures were further supplemented with an anti-human neutralizing antibody to counter 
activity of any endogenously produced TSLP or IL-7. Cultures without a specific 
neutralizing antibody (anti-IL-7 and/or anti-TSLP) were supplemented with an isotype-
matched control for the neutralizing antibody. Anti-human neutralizing or control 
antibody for IL-7 was used at 10 ng/ml (BD Pharmingen, Franklin Lakes, NJ).). Anti-
human neutralizing or control antibody for TSLP was used at 1 ug/ml (R&D Systems and 
Jackson ImmunoResearch, West Grove, PA). Media, cytokines, and antibodies were 
replenished weekly. Cultures were maintained for three weeks, and then harvested. For 
BrdU incorporation, selective cytokine cultures were labeled with 10 PM BrdU (Sigma-
Aldrich, St. Louis, MO) for the final 24 hours of culture. 
 
 
Flow Cytometry 
 
For detection of surface antigens, cells were stained using standard flow 
cytometry protocols, followed by fixation and permeabilization as described below to 
detect intracellular antigens. To discriminate living from dying cells, in some 
experiments, cells were stained with fixable viability dyes (eBioscience, San Diego, CA), 
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per  manufacturer’s  instructions.  Apoptosis  was  quantified by flow cytometry using 
Annexin-V FITC (Biolegend, San Diego, CA) and 7-AAD (eBioscience, San Diego, CA) 
according  to  manufacturer’s  instructions. 
To assess intracellular IgM, Ki-67, Bcl-2, Bcl-xL, and Mcl-1, the Fix & Perm® 
cell fixation and permeabilization kit (Life Technologies, Grand Island, NY)) was used 
according  to  manufacturer’s  instructions.  All  antibodies  were  monoclonal,  anti-human 
antibodies, unless otherwise stated. Intranuclear detection of BrdU was performed using 
BrdU Flow Kit option  no.  2  (BD  Pharmingen)  according  to  manufacturer’s  instructions. 
Briefly, cells were harvested, surface stained, washed then fixed with BD 
cytofix/cytoperm buffer (BD Biosciences) for 15-30 minutes at room temperature. Cell 
suspensions were washed, then stored overnight in freezing medium (90% FBS and 10% 
DMSO) at –80ºC. The following day, thawed cells were washed, re-fixed in BD 
cytofix/cytoperm buffer and washed with BD perm/wash buffer. Cells were treated with 
DNase (300 ug/ml, Sigma-Aldrich) for 1 hour at 37ºC, washed then stained with anti-
BrdU FITC or isotype-matched control for 20 minutes at room temperature. Cells were 
washed then resuspended in 1% PFA for acquisition.  
To assess intracellular PAX-5, cells were first surface stained for viability and 
surface markers, then fixed and permeabilized with FoxP3 fix/perm buffer (eBioscience) 
for 30-60 minutes at 4ºC in the dark. Cells were washed, resuspended in permeabilization 
buffer and stained with PAX-5 PE or isotype-matched controls for 30 minutes at room 
temperature. Cells were washed then resuspended in 1% PFA for acquisition. In some 
experiments, cells were simultaneously stained for PAX-5 and BrdU. In these 
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experiments cells were first stained for PAX-5  according  to  manufacturer’s  directions,  
followed  by  BrdU  staining  according  to  manufacturer’s  instructions. 
 
Table 7: List of Antibodies, Clones and Manufacturer Information 2 (chapter 3) 
 
Antibody Clone Manufacturer 
BrdU FITC B44 BD Biosciences (San Jose, CA) 
Bcl-2 FITC Bcl-2/100 
Ig κ  light  chain  FITC G20-193 
Ig  λ  light  chain  FITC JDC-12 
IgM PE Cy-5  G20-127 
CD19 APC HIB19 
CD34 PerCP 8G12 
CD34 APC 8G12 
CD34 APC.Cy7 581 Biolegend (San Diego, CA) 
IgD PE IA6-2 
Bcl-xL Alexa-fluor 488 54H6 Cell Signaling Technology 
(Beverly, MA) 
CD19 APC HIB19 eBioScience (San Diego, CA) 
CD19 PE.Cy7  SJ25C1 
CD45 PE.Cy7  HI30 
CD127 PE eBioRDR5 
Ig  κ  light  chain  eFluor  450 TB28-2 
Ig  λ  light  chain  eFluor  450 1-155-2 
PAX-5 PE 1H9 
Goat anti-rabbit IgG Alexa Fluor 647  Life Technologies (Molecular 
Probes) (Grand Island, NY) 
Anti-Mouse CD45 FITC 30F11 Miltenyi Biotec (Auburn, CA) 
CD19 APC LT19 
CD34 APC AC136 
CD127 PE MB15-18C9 
Polyclonal Mcl-1  S-19 Santa Cruz Biotechnology  
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Polymerase Chain Reaction 
 
Total RNA was extracted from 8 to 9 x 105 human stromal cells with RNA-STAT 
60 reagent (Tel-Test Inc., Friendswood, TX). cDNA was synthesized using Omniscript 
Reverse Transcriptase (Qiagen, Valencia, CA). The expression of TSLP, IL-7 and E-2 
microglobulin as a control, were assessed by touch down PCR. The primers used were: 
TSLP  forward  5’-TCG TAA ACT TTG CCG CCT AT-3’  and  reverse  5’-TGG TGC TGT 
GAA ATA TGA CCA-3’  (324  bp);;  IL-7  forward  5’- CTC CCC TGA TCC TTG TTC TG 
and  reverse  5’- TCA TTA TTC AGG CAA TTG CTA CC-3’ (151 bp); E-2 
microglobulin  forward  5’-CTC GCG CTA CTC TCT CTT TC-3’  and  reverse  5’-CAT 
GTC TCG ATC CCA CTT AAC-3’  primers. 
Touch-down PCR conditions for TSLP were as follows: 95°C for 5 min (1 cycle); 
95°C for 1 min, 61°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 59°C for 30 
sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 57°C for 30 sec. 72°C for 1 min (2 
cycles); 95°C for 1 min, 55°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 53°C 
for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 51°C for 30 sec. 72°C for 1 min 
(30 cycles); 72°C for 10 min (1 cycle); and final hold step of 4°C.  
Touchdown PCR conditions for IL-7 were as follows: 95°C for 5 min (1 cycle); 
95°C for 1 min, 63°C for 45 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 61°C for 45 
sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 59°C for 45 sec, 72°C for 1 min (2 
cycles); 95°C for 1 min, 57°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 55°C 
for 45 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 53°C for 45 sec. 72°C for 1 min 
(30 cycles); 72°C for 10 min (1 cycle); and final hold step of 4°C.  
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Amplified PCR products were visualized with a 2.2% FlashGel (Lonza, 
Walkerswood, MD). PCR products were purified with QIAquick PCR purification kit 
(Qiagen, Valencia, CA) and sequenced at the Genomics Core (University of California, 
Riverside, CA). 
 
Animal Studies 
 
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
(Jackson Laboratory). Mice were housed under specific pathogen-free conditions in the 
Loma Linda University animal facility and studied in accordance with an Institutional 
Animal Care and Use Committee (IACUC) approved protocols. Mice were transplanted 
by tail vein injection with freshly thawed,  CB CD34+  cells after sub-lethal irradiation at 
225 rads. Mice were engineered by intraperitoneal injection with HS-27 stromal cells 
(ATCC, Manassas, VA) that had been transduced to express human TSLP (+T mice) or 
transduced with empty vector (–T mice) as previously described (4). Transduction of 
stroma and injection of stromal cell is described in the companion paper. NSG mice were 
euthanized by CO2 asphyxiation, five to seven weeks after CB CD34+ transplantation 
and bone marrow and spleen were harvested. Samples were lysed of red blood cells and 
then frozen or stained immediately for flow cytometry analysis. 
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